ABOUT THE MEETING
The Scientific Sessions offers researchers and health care professionals the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care.

Over the course of 5 days, participants will receive exclusive access to more than 2,500 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, expand their professional networks, and so much more.

The program is categorized into 8 distinct theme areas, allowing you to focus on your specialty or expand your knowledge in other areas.

Theme Areas:
- Acute and Chronic Complications
- Behavioral Medicine, Clinical Nutrition, Education, and Exercise
- Clinical Diabetes/Therapeutics
- Epidemiology/Genetics
- Immunology/Transplantation
- Insulin Action/Molecular Metabolism
- Integrated Physiology/Obesity
- Islet Biology/Insulin Secretion

Don’t miss this opportunity to join your colleagues at the world’s largest meeting focused on diabetes—the American Diabetes Association’s 78th Scientific Sessions!

LOCATION AND DATES
The meeting will take place in the West Concourse of the Orange County Convention Center, 9800 International Drive, Orlando, FL.

The program will begin on Friday, June 22 at 11:30 a.m. and conclude on Tuesday, June 26 at 12:15 p.m.

LEARNING OBJECTIVES
The Scientific Sessions offers comprehensive educational programming covering the latest in the field of diabetes. The program is designed for physicians, scientists, researchers, nurses, dietitians, pharmacists, psychologists, and other health care professionals.

At the conclusion of this activity attendees will be able to:
- Identify the 2018 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes.
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia.
- Apply clinical decision-making tools to the assessment and treatment of the complications related to diabetes.
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes.
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes.
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients.
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, transplantation, and islet biology as they relate to diabetes.

MEETING HIGHLIGHTS
Special Addresses and Award Lectures
- President, Health Care & Education Address  
  Felicia Hill-Briggs, PhD, ABPP
- President, Medicine & Science Address  
  Jane E.B. Reusch, MD
- Banting Medal for Scientific Achievement  
  Gerald I. Shulman, MD, PhD
- Outstanding Scientific Achievement Award Lecture  
  Lora K. Heisler, PhD
- Outstanding Educator in Diabetes Award Lecture  
  Jackie Boucher, MS, RD
- Kelly West Award for Outstanding Achievement In Epidemiology Lecture  
  Catherine C. Cowie, PhD
- Richard R. Rubin Award Lecture  
  Tim Wysocki, PhD, ABPP
- Roger Pecoraro Award Lecture  
  Edgar J.G. Peters, MD, PhD
- Norbert Freinkel Award Lecture  
  Linda A. Barbour, MD, MSPH, FACP
- Edwin Bierman Award Lecture  
  Alessandro Doria, MD, PhD, MPH

IMPORTANT DATES TO REMEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Last day to register at the Advance rate</td>
<td>May 10</td>
</tr>
<tr>
<td>Last day to cancel meeting registration and receive a partial refund (50% of registration fee)</td>
<td>May 10</td>
</tr>
<tr>
<td>Last day to reserve hotel rooms</td>
<td>May 25</td>
</tr>
<tr>
<td>Cancel hotel reservations to avoid penalty</td>
<td>72 hours prior to arrival</td>
</tr>
</tbody>
</table>
Earn up to 35 Continuing Education Credits
Credit is available for physicians, nurses, pharmacists, psychologists, dietitians, and certified diabetes educators.

Spotlight on the Sessions
In addition to the over 180 sessions already planned, we are excited to announce that the following sessions will also be presented at this year’s meeting:
- Real-World Evidence in Diabetes
- Lessons Learned from the Environmental Determinants of Diabetes in the Young (TEDDY) Study—Insights into Early Autoimmune Type 1 Diabetes
- The Veterans Affairs Diabetes Trial (VADT) at 15 Years
- The Restoring Insulin Secretion (RISE) Study in Youth and Adults—Baseline Data and Results of the Pediatric Medication Study
- Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018
- SGLT Inhibition for Type 1 Diabetes Mellitus Management—How Far Have We Gone?

Visit scientificsessions.diabetes.org for more information on these evolving sessions.

Mini-Symposia
Mini-Symposia are 1-hour sessions that normally include 1-2 speakers. Speakers present on a topic for a maximum of 20 minutes with the remainder of the time devoted to questions and discussion with the audience.

Professional Interest Groups
Professional Interest Group Sessions are held Saturday, Sunday, and Monday during the lunchtime hour. Expect lively conversations, dialogue, and debate.

Interest Groups contribute to the ADA in a variety of valuable ways throughout the year, with members serving on policy-making committees, writing technical reviews, writing position statements, and acting as liaisons with peer organizations. Visit professional.diabetes.org/interestgroups for the latest resources and information.

Oral Presentations
Abstracts selected for oral presentation are considered to be the best of the thousands of abstracts submitted to the Scientific Sessions. Choose from 375 original presentations highlighting the most innovative research not found at any other meeting.

Poster Presentations
Explore more than 2,000 posters displaying the latest investigative methods in the Poster Hall on Saturday, Sunday, and Monday. Poster presenters will be at their poster boards for 1-hour on an assigned day to discuss their research with attendees.

Moderated Poster Discussions
Moderators will lead attendees on tours of select posters sharing their perspectives and highlighting novel or recent advancements in question and answer discussions with presenters. Discussions will take place on Saturday, Sunday, and Monday in the Poster Hall.

Due to the overwhelming popularity of the moderated poster discussions, select discussions will be presented in our ePoster Theaters. The ePoster Theaters accommodate larger crowds and make for a much more comfortable and enjoyable learning experience.

Interactive Online Posters
Unable to meet with a poster presenter? Each poster presented at the Scientific Sessions will have a corresponding barcode on its board. Scan the barcode with your smartphone, tablet, or handheld device to access an electronic version of the poster, corresponding abstract, and audio commentary (if provided). Computer stations will also be located within the Poster Hall for electronic poster viewing.

Scientific Sessions App
Access the meeting on-the-go. Download the Scientific Sessions meeting app to access information on your smartphone, tablet, or handheld device.

Visit scientificsessions.diabetes.org in May for more details.

EXHIBIT HALL
The Exhibit Hall showcases products and services that will enhance your understanding of the latest ground-breaking technology and resources available today. The Exhibit Hall will be open on Saturday, Sunday, and Monday.

PRODUCT THEATERS
Industry experts will provide insight into diabetes services and products and demonstrate innovative equipment and technologies. Product Theaters will be scheduled during morning, lunch, and afternoon breaks in the Exhibit Hall on Saturday, Sunday, and Monday.

Product Theater content is the sole responsibility of the supporting company and is not part of the official education offered by the ADA at the Scientific Sessions.
ADVANCE PROGRAM

CORPORATE SYMPOSIA
Corporate Symposia are satellite programs that are planned and conducted by the corporate community in conjunction with the Scientific Sessions. These programs provide attendees with additional education and information opportunities. Pre-registered attendees will receive an e-mail on or about April 3, which will include instructions on registering for the Corporate Symposia. Attendees who register after April 3 will be able to select the Corporate Symposia when registering. All programs will take place at the Hyatt Regency Orlando.

Visit scientificsessions.diabetes.org in early-April for the most up-to-date schedule.

Corporate Symposia content is the sole responsibility of the supporting company and is not part of the official education offered by the ADA at the Scientific Sessions.

WOMEN’S INTERPROFESSIONAL NETWORK
The Women’s Interprofessional Network of the American Diabetes Association (WIN ADA) is a membership benefit for women in medicine, science, health care, and education. Join WIN ADA for an interactive session on overcoming gender gaps in science on Monday, June 25, from 12:00 p.m.-1:00 p.m. Hear from leading women in diabetes, and share your experiences during the session’s open discussion. WIN ADA will also hold its own networking event during the Scientific Sessions Networking Reception on Friday, June 22, at 6:30 p.m.-8:30 p.m. Learn more at professional.diabetes.org/winada.

DIABETES IS PRIMARY
This interactive program, developed specifically for the primary care community, and held as a Scientific Sessions preconference, will offer information needed to improve patient outcomes and enhance patient engagement. The program will be held on Friday, June 22, from 8:00 a.m.-3:00 p.m. at the convention center.

The $100 registration fee includes admission, continuing education credits, course materials, and lunch. Scientific Sessions attendees can sign up for Diabetes Is Primary when registering for the Scientific Sessions.

Please note: Diabetes Is Primary overlaps with other sessions held on Friday, June 22, starting at 11:30 a.m.

SPECIAL EVENTS
Networking Reception
Join us Friday evening from 6:30 p.m. to 8:30 p.m. at the Orange County Convention Center to meet and network with your colleagues from across the country and around the world. This is a great opportunity to renew connections with friends and colleagues or make new ones. Light hors d’oeuvres and refreshments will be provided.

5K@ADA Fun Run/Walk
The 5K@ADA Fun Run/Walk, supported by Novo Nordisk, will be held on Sunday morning at 6:30 a.m. Race in style by sporting a 5K@ADA running shirt available for $20 when you register for the meeting. A limited number of shirts will be available for purchase onsite for $25. Sign up for the Fun Run/Walk by visiting tracs.net/ADA5K. The event is free to all registered attendees.

FIFA (World Cup) Viewing Lounge
You don’t have to miss sessions to keep up with the 2018 FIFA World Cup. Pop by the World Cup Viewing Lounge between sessions to see how your favorite team is doing.

Support the American Diabetes Association by Wearing Red
Wear red on Sunday to show your support of the ADA and our mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Red merchandise is available for purchase in advance from shopdiabetes.org or onsite at the Shop Diabetes Store. Every purchase supports diabetes research, advocacy, awareness, and education programs.

CITY INFORMATION
With 7 of the world’s top 20 theme parks in one destination, Orlando certainly knows how to entertain. After walking the convention center floor or incorporating a pre- or post-stay, a leisurely escape to a world of imagination and fantasy will leave you feeling refreshed and inspired. Whether seeking to reconnect with childhood nostalgia or experience leading-edge innovations in ride technology, these latest additions are truly one-of-a-kind.

For more information on Orlando, visit ada2018.orlandomeetinginfo.com/things-to-do/.
REGISTRATION RATES

<table>
<thead>
<tr>
<th></th>
<th>ADVANCE</th>
<th>FINAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3/9/18 - 5/10/18</td>
<td>5/11/18 - 6/26/18</td>
</tr>
<tr>
<td>Member*</td>
<td>$555</td>
<td>$605</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$875</td>
<td>$925</td>
</tr>
<tr>
<td>Student/Resident/Fellow</td>
<td>$300</td>
<td>$320</td>
</tr>
<tr>
<td>One-Day Registration — Member*</td>
<td>$310</td>
<td>$320</td>
</tr>
<tr>
<td>One-Day Registration — Non-Member</td>
<td>$400</td>
<td>$410</td>
</tr>
</tbody>
</table>

*In order to qualify for the Member rate your Professional I (Science & Medicine) or Professional II (Health Care & Education) Membership must be active through June 30, 2018 at the time of registration.

REGISTRATION CATEGORIES

**Member**
Professional I (Science & Medicine) or Professional II (Health Care & Education) Members. Have your Professional Member ID number available to register as a member. Professional Members who purchase a full meeting registration will receive online access to the Scientific Sessions webcasts free of charge!

**Non-Member**
For those who are not ADA Professional I (Science & Medicine) or Professional II (Health Care & Education) Members. Become a member when you register for the Scientific Sessions and save up to $320 on your registration.

**Student/Resident/Fellow**
Available to those currently enrolled in 1 of these programs. Proof of status in a program must be submitted in order to register.

**One-Day**
Provides admittance to all sessions, including the Exhibit Hall and the Poster Hall (if open), for the selected day. You are allowed to register for only 1 One-Day Registration.

**Please note:**
Children under the age of 18, even if paid registrants, will not be permitted access to session rooms, the Exhibit Hall, or the Poster Hall. Exceptions can be made for nursing mothers, but for safety reasons, strollers cannot be allowed.

**Register Online**
Go to scientificsessions.diabetes.org and click on the Registration Information tab. Online registration is fast, easy, and secure. You will receive your confirmation letter and periodic updates via e-mail. If you are unable to register online, a downloadable registration form is available on the Scientific Sessions website. Attendees should bring their confirmation letter with them onsite to receive their meeting materials. The barcode included on your confirmation letter will greatly speed you through registration. A picture ID will be required to pick up your registration materials.

**Media Registration**
The ADA provides complimentary access to the Scientific Sessions to credentialed members of the media, including print, broadcast and online media for the express purpose of gathering news and information to produce press coverage of the 78th Scientific Sessions. Media representatives welcome to attend include reporters, writers, photographers and videographers. News organizations seeking media credentials must be represented by editorial staff, and media registration is limited to 2 individuals per outlet/news organization.

For further information regarding registration eligibility and submission requirements for your news organization, contact press@diabetes.org with any questions.

**Questions?**
Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Visit the ADA Support Center at ada.cmrushelp.com.
**HOTEL INFORMATION**

Go to scientificsessions.diabetes.org and click on the Hotel Information tab. Reserving your room online allows you to see hotel availability in real-time and allows us to send confirmation letters instantly. It also gives us a fast and easy way to contact you via e-mail with any changes or updates.

**Hotel Reservations**

Support the ADA by booking your hotel room within the Scientific Sessions housing block through our official housing company, CMR. Hotel reservations can be made until May 25 based on availability. A listing of official ADA hotels, with rates and a locator map, is available at scientificsessions.diabetes.org. Reservations are available on a first-come, first-served basis. Reserve your room early for the best selection. All hotels require a credit card guarantee. If you are unable to reserve online, a downloadable housing form is available on the Scientific Sessions website.

**ADA Shuttle Bus Transportation**

Attendees who reserve their room within the Scientific Sessions housing block will receive a shuttle pass, enabling them to ride the ADA shuttle system at no additional cost. Attendees who reserve their rooms through other means will not receive a shuttle pass. Shuttle passes will be available for purchase in advance through the registration site and onsite at the meeting at a cost of $75 per person. The pass is valid throughout the duration of the meeting.

**International Group Organizers**

If you are organizing an international group (five or more rooms) to attend the Scientific Sessions, you may reserve your hotel rooms through our official housing company’s International Group Division, CMR’s Global Group Services website at ada-cmrglobalgroupservices.com, or contact them via e-mail at ada@cmr-globalgroupservices.com for an all-inclusive group housing package. For any questions regarding group registration, visit the ADA Support Center at ada.cmrushelp.com.

**Hotel Cancellations and Changes**

All requests for cancellations or changes can be made by going online or by contacting ADA’s official housing company. Changes received after May 25 will be subject to hotel availability. Reservations must be cancelled at least 72 hours prior to arrival to avoid penalty charges.

**Questions?**

Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +1-268-2086 (International). Visit the ADA Support Center at ada.cmrushelp.com.

**TRAVEL INFORMATION**

**Special Travel Discounts**

The ADA is pleased to offer travel discounts for Delta Air Lines, Southwest Airlines, United Airlines, Avis and Hertz car rentals, and SuperShuttle airport transportation for the Scientific Sessions.

Visit scientificsessions.diabetes.org and click on the Travel and Transportation Information tab for more information.

**Visa Requirements**

Attendees from outside the U.S. may need to apply for a visa at the American Embassy, consulate, or other visa issuing office in their country of origin. Please begin your visa application process as soon as possible, as it can take several months to receive approval.

If a letter of invitation is needed for your visa application, go to scientificsessions.diabetes.org and click on the Travel and Transportation Information tab to download the letter.
ACCREDITATION STATEMENTS

Physicians
The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Diabetes Association designates this live activity for a maximum of 35 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Family Physicians
An application for CME credit will be filed with the American Academy of Family Physicians.

Doctors of Osteopathy
Category 2 Credit will be awarded for formal educational programs that are ACCME-accredited or AAFP approved.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME for a recognized state medical society. Physician Assistants may receive a maximum of 35 hours of Category 1 Credit™ for completing this program.

International Physicians
The American Medical Association has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 credit(s)™.

European Union of Medical Specialists
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby: 1) European physicians attending an event in the USA had their credits recognized in Europe and 2) American physicians attending an event in Europe had their credits recognized in the USA. The American Diabetes Association designates this educational activity for a maximum of 35 AMA PRA Category 1 Credit(s)™ for the American Diabetes Association’s 78th Scientific Sessions. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Nurses
The American Diabetes Association is accredited as a provider of continuing education by the American Nurses Credentialing Center’s COA.

California Board of Registered Nursing
The American Diabetes Association is a provider approved by the California Board of Registered Nursing. Provider No. CEP-12196. This activity is approved for 35 contact hours.

Dietitians
The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians will receive 35 continuing professional education units (CPEUs) for completion of this program/material. Activity Number: 138560.

Pharmacists
The American Diabetes Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Provider number 0239. The American Diabetes Association designates these sessions as Knowledge-based per ACPE guidelines. To view the UANs and learning objectives for each educational category, visit scientificsessions.diabetes.org and click on the Continuing Education tab.

Psychologists
The American Diabetes Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The American Diabetes Association maintains responsibility for the program and its content. This activity offers a maximum of 35 hours of continuing education credit. Each psychologist must attend in their entirety those sessions designated as offered for psychology credit and claim only those hours spent in the educational activity.

Certified Diabetes Educators
To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (ncbde.org). NCBDE does not approve continuing education. The American Diabetes Association is on the NCBDE List of Approved Providers.

Successful Completion Statement
Certificates of Completion/Attendance are provided to registered attendees based upon completion of the online evaluation. The online evaluation will be emailed to registered attendees and will be available at scientificsessions.diabetes.org from June 22 to July 27, 2018.

For questions regarding continuing education, e-mail professional education@diabetes.org.
### DAY-AT-A-GLANCE SCHEDULE
#### FRIDAY, JUNE 22, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 p.m.—1:45 p.m.</td>
<td>Mini-Symposium Surveillance of Kidney Disease and Comorbidities among People with Diabetes—What We Can Learn from the CDC’s Chronic Kidney Disease Surveillance System</td>
<td>Mini-Symposium Understanding Hybrid Closed-Loop Pump Youth-Onset Type 2 Diabetes and Exercise—Outcomes and Challenges</td>
<td>Mini-Symposium Better Ways to Build Diabetes Population Health Management Challenging Times for Youth with Type 1 Diabetes—How Do We Approach Them?</td>
<td></td>
<td>Mini-Symposium The Future of Islet Transplant—Towards a Renewable Source of Beta Cells</td>
<td>Mini-Symposium Near, Far, Wherever You Are—Obesity-Related Defects in Insulin Signaling</td>
<td></td>
<td>Mini-Symposium Of Mice, Mongrels, and Men—Commonalities and Differences in Metabolic Research</td>
</tr>
<tr>
<td>Time</td>
<td>Section</td>
<td>Symposium</td>
<td>Symposium</td>
<td>Symposium</td>
<td>Symposium</td>
<td>Symposium</td>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>2:00 p.m.—4:00 p.m.</td>
<td>Acute and Chronic Complications</td>
<td>Symposium Antiplatelet and Antithrombotic Therapies in Diabetes</td>
<td>Symposium Decreasing Risk for Type 2 Diabetes with Foods</td>
<td>Symposium Artificial Pancreas and Decision Support Approaches Real-World Evidence in Diabetes</td>
<td>Symposium Mental Health Disorders and Diabetes Distress among Adults with Diabetes</td>
<td>Symposium Endocrine, Paracrine Signaling Affecting Adipocyte Function</td>
<td>Symposium Transformational Technologies in Islet Biology—From Omics to Imaging</td>
<td></td>
</tr>
<tr>
<td>4:15 p.m.—6:15 p.m.</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td>Symposium The Many Faces of Hypoglycemia—Impact on Patient Health and Well-Being</td>
<td>Symposium Data, Data, Everywhere and Not a Pattern to Be Found</td>
<td>Symposium (4:15 p.m.—5:10 p.m.) Cardiovascular Outcomes Trials (CVOTs) in Diabetes—Shall We Continue or Change Course?</td>
<td>Symposium (5:20 p.m.—6:15 p.m.) Should Metformin Remain the First-Line Therapy for Type 2 Diabetes?</td>
<td>Symposium Mental Health Disorders and Diabetes Distress among Adults with Diabetes</td>
<td>Symposium Transformational Technologies in Islet Biology—From Omics to Imaging</td>
<td></td>
</tr>
<tr>
<td>6:30 p.m.—8:30 p.m.</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Networking Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## DAY-AT-A-GLANCE SCHEDULE
### SATURDAY, JUNE 23, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:00 a.m.—10:00 a.m. | **Symposium** Is It Osteomyelitis or Not? Diagnostic and Treatment Dilemmas in Bone Infection  
**Oral Presentations** |
| 10:15 a.m.—11:15 a.m. | President, Health Care & Education Address and Outstanding Educator in Diabetes Award Lecture  
**Oral Presentations** |
| 11:30 a.m.—12:30 p.m. | **Professional Interest Group Session** The Best and Worst Practices in Managing the Diabetic Foot  
**Professional Interest Group Sessions** Update on Nonnutritive Sweeteners and Cardiometabolic Health  
Reframing Exercise—The Surprising Science behind Motivating Patients to Be More Physically Active  
**Mini-Symposium** Quantifying Diabetes—Genomics, Electronic Health Records, and Automated Control  
**General Poster Session**  
**Moderated Poster Discussions** |
<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45 p.m.—3:45 p.m.</td>
<td>Symposium The Resurgence of Triglyceride-Rich Lipoproteins as an Important Target in the Treatment of Dyslipidemia</td>
<td>Symposium Making a Difference in Five Minutes—Interventions in Diabetes for Anyone (With Richard R. Rubin Award Lecture)</td>
<td>Symposium National Implementation and Dissemination of Research to Improve Patient Safety and Reduce Hypoglycemia</td>
<td>Case Studies Monogenic Diabetes Testing Is Ready for Prime Time—Integrating Genetics into Your Practice</td>
<td>Oral Presentations</td>
<td>Symposium The Intestine in the Regulation of Metabolism, Immunity, and Insulin Sensitivity</td>
<td>Symposium Steering the Right Course for Diabetes Management—Clinical Perspectives</td>
<td>Symposium Beta-Cell Dedifferentiation—True or False?</td>
</tr>
<tr>
<td>4:00 p.m.—6:00 p.m.</td>
<td>Oral Presentations Roger Pecoraro Award Lecture</td>
<td>Symposium Nutrition and the Gut Microbiome Online and Mobile Support—Wading through the Noise</td>
<td>Symposium Joint ADA/ISPAD Symposium—25 Years after the Announcement of the DCCT Results—What Is the Status of Type 1 Diabetes in Youth, and How Can We Do Better?</td>
<td>Oral Presentations</td>
<td>Oral Presentations</td>
<td>Symposium Mitochondrial Dynamics, Metabolism, and Insulin Action</td>
<td>Oral Presentations</td>
<td>Symposium Neurotransmitters in the Islet</td>
</tr>
<tr>
<td>Time</td>
<td>Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 8:00 a.m.—10:00 a.m. | **Symposia**  
The Where and Why of Diabetic Neuropathy  
Symposia Building a Case for Getting Reimbursement or Payment for Behavioral Health in Diabetes  
NDEP Symposium—Diabetes Prevention, Care, and Education in the Digital Age  
**Oral Presentations**  
Preventing Nutritional Vascular Complications  
Oral Presentations  
**Mini-Symposium**  
The Importance of the Functional Characteristics of HDL  
Update on Diabetic Retinopathy Clinical Trials |
| 10:15 a.m.—11:45 a.m. | President, Medicine & Science Address and Banting Medal for Scientific Achievement  
**Mini-Symposium**  
The Importance of the Functional Characteristics of HDL  
Update on Diabetic Retinopathy Clinical Trials |
| 12:00 p.m.—1:00 p.m. | **Professional Interest Group Sessions**  
Moving Past the Randomized Controlled Trial—Understanding the Need for Implementation Science in Diabetes Care  
The Future of Diabetes Education—“Live” Educator and “Virtual” Coach Partners in Care  
**Professional Interest Group Sessions**  
Beyond HbA1c in Pediatric Diabetes—Is It Time to Look at Other Outcomes?  
Clinical Centers and Programs Session I  
**Mini-Symposium**  
Update on the Genetics of Type 1 and Type 2 Diabetes  
General Poster Session/Moderated Poster Discussions  
Session Break (Take this opportunity to visit the Exhibit and Poster Halls) |
## DAY-AT-A-GLANCE SCHEDULE
### SUNDAY, JUNE 24, 2018—WEAR RED DAY (CONTINUED)

<table>
<thead>
<tr>
<th>2:15 p.m.—4:15 p.m.</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium</strong></td>
<td>2:15 p.m.—3:00 p.m.</td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Symposium</td>
<td>to Improve the Inpatient</td>
<td>to Improve the Inpatient Experience</td>
<td>Program—from Research to</td>
<td>Achievement in</td>
<td>—Lipidic Roles in Different</td>
<td>Management</td>
<td>Weight-Loss Menu in the</td>
<td>in the Beta Cell</td>
</tr>
<tr>
<td>Management of</td>
<td>Experience</td>
<td>Program—from Research to Practice to National Policy</td>
<td>Epidemiology</td>
<td>Achievement in</td>
<td>Tissues</td>
<td>Management</td>
<td>Era of Precision Medicine for</td>
<td></td>
</tr>
<tr>
<td>Patients with</td>
<td>Aerobic Exercise in</td>
<td>Joint ADA/JDRF Symposium—Current Management of Type 1</td>
<td>Epidemiology</td>
<td>Achievement in</td>
<td></td>
<td></td>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>Progressing Diabetic</td>
<td>the Prevention of</td>
<td>Diabetes in Youth—What Are the Options?</td>
<td>Lecture</td>
<td>Epidemiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney Disease</td>
<td>Cognitive Decline in Diabetes</td>
<td>Addressing Unique Challenges in Diabetes Management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(DKD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4:30 p.m.—6:30 p.m.</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Vascular Effects in</td>
<td></td>
<td>Diets—Potential Benefits, Risks, and Costs</td>
<td>Are We Preventing?</td>
<td>Collaborations—Key</td>
<td>—Lipidic Roles in Different</td>
<td>Management</td>
<td>Weight-Loss Menu in the</td>
<td>in the Beta Cell</td>
</tr>
<tr>
<td>the Pathogenesis of</td>
<td></td>
<td></td>
<td></td>
<td>Considerations</td>
<td>Tissues</td>
<td>Management</td>
<td>Era of Precision Medicine for</td>
<td></td>
</tr>
<tr>
<td>Diabetic Nephropathy</td>
<td></td>
<td></td>
<td></td>
<td>Beyond Single</td>
<td></td>
<td></td>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nucleotide Polymorphisms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Veterans Affairs</td>
<td></td>
<td></td>
<td></td>
<td>Building on Knowledge</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Trial (VADT)</td>
<td></td>
<td></td>
<td></td>
<td>of the Genetic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>at 15 Years</td>
<td></td>
<td></td>
<td></td>
<td>Architecture of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
<td></td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4:30 p.m.—6:30 p.m.</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Academy-Industry</td>
<td></td>
<td>Low-Carbohydrate</td>
<td>Diabetes Prevention—What</td>
<td>Academic-Industry</td>
<td>Fuel Driving Function</td>
<td>Cell Therapy</td>
<td>Ordering from the</td>
<td>More to Mitochondria</td>
</tr>
<tr>
<td>Collaborations—Key</td>
<td></td>
<td>Diets—Potential Benefits, Risks, and Costs</td>
<td>Are We Preventing?</td>
<td>Collaborations—Key</td>
<td>—Lipidic Roles in Different</td>
<td>Management</td>
<td>Weight-Loss Menu in the</td>
<td>in the Beta Cell</td>
</tr>
<tr>
<td>Considerations</td>
<td></td>
<td></td>
<td></td>
<td>Considerations</td>
<td>Tissues</td>
<td>Management</td>
<td>Era of Precision Medicine for</td>
<td></td>
</tr>
<tr>
<td>Beyond Single</td>
<td></td>
<td></td>
<td></td>
<td>Building on Knowledge</td>
<td></td>
<td></td>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>Nucleotide Polymorphisms</td>
<td></td>
<td></td>
<td></td>
<td>of the Genetic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building on</td>
<td></td>
<td></td>
<td></td>
<td>Architecture of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knowledge of the</td>
<td></td>
<td></td>
<td></td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetic Architecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Registration Hours: 7:30 a.m.—5:00 p.m.
Shop Diabetes Store Hours: 7:30 a.m.—6:45 p.m.
Exhibit Hall Hours: 10:00 a.m.—4:00 p.m.
Poster Hall Hours: 7:30 a.m.—6:30 p.m.
<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.—10:00 a.m.</td>
<td><strong>Acute and Chronic Complications</strong></td>
<td>Symposium Role of the Kidney in Heart Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</strong></td>
<td>Symposium Intervening in the Lived Experiences and Social Context of Those with Diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Clinical Diabetes/Therapeutics</strong></td>
<td>Symposium Who Do You Think You Are? Heterogeneity of Obesity and Gestational Diabetes Mellitus</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Epidemiology/Genetics</strong></td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Immunology/Transplantation</strong></td>
<td>Symposium Clinical Trials for Type 1 Diabetes—Current, Emerging, and Novel</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Insulin Action/Molecular Metabolism</strong></td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Integrated Physiology/Obesity</strong></td>
<td>Symposium Recognition of Depression, Diabetes, and Dementia—Resetting Clinical Priorities</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Islet Biology/Insulin Secretion</strong></td>
<td>Symposium Metabolism and the Beta Cell</td>
<td></td>
</tr>
<tr>
<td>10:15 a.m.—11:45 a.m.</td>
<td><strong>Symposium</strong></td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>National Scientific &amp; Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.—1:00 p.m.</td>
<td><strong>Mini-Symposium</strong></td>
<td>Special Topics in Hypoglycemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mini-Symposium Overcoming Gender Gaps in Science</strong></td>
<td>Overcoming Gender Gaps in Science</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Professional Interest Group Sessions</strong></td>
<td>The Lancet Commission on Diabetes—Societal Solutions to Combat Diabetes</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Professional Interest Group Session</strong></td>
<td>Should All Pregnant Women with Type 1 Diabetes Use Continuous Glucose Monitoring from Planning Pregnancy until after Breastfeeding?</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Professional Interest Group Session</strong></td>
<td>Defining a Healthy Diet—Do Fats or Carbohydrates Matter More?</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Professional Interest Group Session</strong></td>
<td>Immunopathogenesis of Type 1 Diabetes—Is It Autoimmunity?</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.—1:00 p.m.</td>
<td><strong>Clinical Centers and Programs Session II</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>General Poster Session/Moderated Poster Discussions</strong></td>
<td>General Poster Session/Moderated Poster Discussions</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</strong></td>
<td>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15 p.m.</td>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute and Chronic Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vivian Fonseca-Nagendran Award Presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost-Related Nonadherence to Diabetes Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Restoring Insulin Secretion (RISE) Study in Youth and Adults—</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Baseline Data and Results of the Pediatric Medication Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adipose Signaling and the Central Nervous System in the Control of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Current Issues</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Two Debates</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>About Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute and Chronic Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Strategies for Prevention and Management of Hypoglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Using mHealth for Obesity Treatment and Weight Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Using a Little Science for a Big Impact</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symposium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## DAY-AT-A-GLANCE SCHEDULE
### TUESDAY, JUNE 26, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.—10:00 a.m.</td>
<td><strong>Symposium</strong> Cardiorenal Effects of Glucose-Lowering Therapies</td>
<td><strong>Symposium</strong> Multigenerational Effects of Exercise</td>
<td><strong>Symposium</strong> Management of Diabetes in a Surgical Patient</td>
<td><strong>Symposium</strong> Diabetes in Rural America</td>
<td></td>
<td></td>
<td></td>
<td><strong>Symposium</strong> G-Protein-Coupled Receptors—Structural Insights to Therapeutic Options</td>
</tr>
<tr>
<td>10:15 a.m.—12:15 p.m.</td>
<td><strong>Symposium</strong> SGLT Inhibition for Type 1 Diabetes Mellitus Management—How Far Have We Gone?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**SCIENTIFIC PROGRAM**

**FRIDAY, JUNE 22, 2018**

**11:30 a.m.-12:30 p.m.**

**Mini-Symposia**

- **Measuring Neuropathy—Is Corneal Confocal Microscopy Ready for Prime Time?**
  - Yes, Corneal Confocal Microscopy Is Ready for Clinical Trials and Practice
  - Bruce A. Perkins, MD, MPH
  - Not So Fast, Corneal Microscopy Is Not as Good as the Tried and True
  - J. Robinson Singleton, MD

- **Biofilm—Real Wound Problem or Just a Buzzword?**
  - Biofilm—Invisible Barrier to Wound Healing
  - Elizabeth A. Grice, PhD
  - Biofilm—It’s Invisible Because It’s Not There
  - Lawrence A. Lavery, DPM

- **Tech and Teens**
  - Texting Teens to Improve Management and Reduce Diabetic Ketoacidosis
  - David V. Wagner, PhD
  - The Value of Apps, or Lack Thereof, for Teens with Diabetes
  - Sarah S. Jaser, PhD
  - To Share or Not to Share, Do Teens Care?
  - Korey K. Hood, PhD

- **Myth or Science—Current Fads and Evidence in Diet and Nutrition**
  - Panel Discussion
  - Catherine M. Champagne, PhD, RDN, LDN, FADA, FAND, FTOS
  - Melinda D. Maryniuk, MEd, RD, CDE

- **Innovations in Diabetes Pregnancy Care**
  - Community Models of Care
  - Maribeth Inturrisi, RN, MS, CNS, CDE
  - Healthy Mothers on the Move—A Community Health Worker-Led Diabetes Prevention Intervention for Pregnant and Postpartum Latinas
  - Edith C. Kieffer, PhD, MPH

**12:45 p.m.-1:45 p.m.**

**Mini-Symposia**

- **New-Onset Type 2 Diabetes in the Youngest and the Oldest**
  - Type 2 Diabetes in Children, Adolescents, and Young Adults
  - Sharon Saydah, PhD
  - New-Onset Type 2 Diabetes among the Elderly
  - Hermes Florez, MD

- **The Emerging Role of Neoepitopes in the Dialogue between T Cells and Beta Cells**
  - Posttranslational Modifications in Type 1 Diabetes and Other Autoimmune Disorders
  - Mark J. Mamula, PhD
  - Generation and Recognition of Neoepitopes in Subjects with Type 1 Diabetes
  - Eddie A. James, PhD

- **Insulin Resistance Pathobiology—Insulin Secretion vs. Peripheral Insulin Action—A Banting Exchange**
  - Panel Discussion
  - Richard N. Bergman, PhD
  - Barbara E. Corkey, PhD

- **New Regulators of Beta-Cell Identity**
  - 3-D Chromatin Maps, Beta-Cell Identity, and Diabetes
  - Jorge Ferrer, MD, PhD
  - Intermittent Fasting and Beta-Cell State
  - Julie B. Sneddon, PhD

- **Understanding Hybrid Closed-Loop Pump**
  - What Clinicians Need to Know
  - Elizabeth Ann Doyle, DNP, APRN, CDE

- **Youth-Onset Type 2 Diabetes and Exercise—Outcomes and Challenges**
  - Exercise Dose and Diabetes Risk in Overweight and Obese Children
  - Catherine L. Davis, PhD
  - Changing the School of Thought on Metabolic Health in Children by Creating an ACTIVE Classroom
  - Rebecca E. Hasson, PhD

- **Better Ways to Build Diabetes Population Health Management**
  - Population Health Management in Underserved Communities
  - Luigi F. Meneghini, MD, MBA
  - Nurse Care Managers and Medical Assistant Coaches to Improve Quality Outcomes
  - Addie L. Fortmann, PhD

- **Challenging Times for Youth with Type 1 Diabetes—How Do We Approach Them?**
  - The Toddler Years—Depending on Parental/Guardian Support
  - Michelle A. Van Name, MD
  - Being a Young Adult and Transitioning to Adult Care
  - Katharine C. Garvey, MD, MPH

- **The Future of Islet Transplant—Towards a Renewable Source of Beta Cells**
  - Stem Cells Will Be the Future Source of Beta Cells
  - Jon S. Odorico, MD, FACS
  - Genetically-Engineered Pigs Will Be the Future Source of Beta Cells
  - David K.C. Cooper, MD, PhD, FRCS

Speakers and presentation titles are subject to change.
• Near, Far, Wherever You Are—Obesity-Related Defects in Insulin Signaling
  Proximal Mechanisms Mediate Impaired Responses to Insulin
  Varman Samuel, MD, PhD
  Downstream Defects in Insulin Signaling in Obesity
  Michael P. Czech, PhD
  Question and Discussion Period

• Of Mice, Mongrels, and Men—Commonalities and Differences in Metabolic Research
  Mouse Models in Research—How Translatable Is the Data?
  Jason K. Kim, PhD
  Dogs, Pigs, and Primates—A Bridge Between Mice and Men
  Dale S. Edgerton, PhD
  Are Humans Becoming the Optimum Model for Diabetes Research?
  Eugene J. Barrett, MD, PhD
  Question and Discussion Period

2:00 p.m.-4:00 p.m.
Symposia
• Antiplatelet and Antithrombotic Therapies in Diabetes
  Aspirin for Primary Cardiovascular Risk Intervention—What’s the Evidence in Patients with Diabetes?
  Rita Rastogi Kalyani, MD, MHS
  Utility of Combination Antiplatelet Therapies in Diabetes
  Deepak L. Bhatt, MD, MPH
  Update on Novel Anticoagulants
  Jacob A. Udell, MD, MPH, FRCPC

• Decreasing Risk for Type 2 Diabetes with Foods
  Mediterranean Diet to Reduce Risk for Type 2 Diabetes
  Catherine Itsiopoulos, BSc, BSc (Hons), Grad Dip Diet, MPH, PhD, APD, AN
  The Role of Dairy Food in Diabetes Risk Reduction
  Joanna Mitri, MD, MS
  Plant-Based Diets to Reduce Risk for Type 2 Diabetes
  David Jacobs, PhD
  Red and Processed Meats—Do They Really Increase Risk for Type 2 Diabetes?
  Sylvia H. Ley, PhD, RD

• Artificial Pancreas and Decision Support Approaches
  Advanced Treatments for Type 1 Diabetes—Adapting to Meals and Exercise
  Jessica R. Castle, MD
  Continuous Glucose Monitoring-Based Decision Support for Type 1 Diabetes
  Marc D. Breton, PhD
  The Path to a Medical Internet of Things (IoT) and Human-Centric Design of an Artificial Pancreas
  Eyal Dassau, PhD
  Automated Adjustment of Basal-Bolus Insulin Therapy Using Run-to-Run Control and Case-Based Reasoning
  Pau Herrero-Viñas, PhD
  Multivariable Adaptive Artificial Pancreas Systems
  Ali Cinar, PhD

• Real-World Evidence in Diabetes
  Closing the Evidence Gaps with Real-World Evidence in Diabetes
  Kamlesh Khunti, MD, PhD, FRCGP, FRCPC
  Real-World Evidence Studies—Methodological Approaches to Overcome Bias
  Sean D. Sullivan, BScPharm, PhD
  Combining Methodological Approaches to Assess Efficacy and Safety of Gla-300 vs. First-Generation Basal Insulins—A Case Study
  Timothy S. Bailey, MD, FACE, CPI
  From Traditional to Innovative Methodological Approaches to Assess Efficacy and Safety of Gla-300 vs. Second-Generation Basal Insulins—A Case Study
  Lawrence Blonde, MD
  Complementing Randomized Controlled Trials with Real-World Evidence—A Comprehensive Evidence-Generation Program in Patients with Diabetes
  Stewart Harris, CM, MD, MPH, FCFP, FACPM

• Mental Health Disorders and Diabetes Distress among Adults with Diabetes
  The Epidemiology and Impact of Mental Health Disorders among Adults with Diabetes
  Mary de Groot, PhD
  Diabetes among Patients with Complex Mental Health Disorders and with Use of Antipsychotic Medications—Implications for Screening and Management
  John W. Newcomer, MD
  Caring for the Whole Patient—Best Practices for Managing Mental Health Disorders and Diabetes
  Mark D. Williams, MD
  Diabetes Distress—Epidemiology, Impact, and Treatment
  Kathryn Evans Kreider, DNP, FNP-BC, BC-ADM

• Endocrine, Paracrine Signaling Affecting Adipocyte Function
  Cardiac-Adipocyte Cross Talk through Natriuretic Peptide Signaling
  Sheila Collins, PhD
  Brain-Derived Neurotrophic Factor and Brain-Adipocyte Cross Talk
  Lei Cao, PhD
  Sympathetic Input Regulating Lipolysis and Thermogenesis in White and Brown Adipose Tissue
  Kristin I. Stanford, PhD
  Beta-Adrenergic Signaling Regulates a Concerted Thermogenic Response in Brown Adipose Tissue and Subcutaneous White Adipose Tissue
  Juro Sakai, MD, PhD

• The Exosome Superhighway in Energy and Metabolic Homeostasis
  Adipose-Derived Exosomal MicroRNAs Regulate Gene Expression in Other Tissues
  C. Ronald Kahn, MD
  Islet-Derived Extracellular Vesicles and Their Immunological Potential
  Steven Paraskevas, MD, PhD
  Exosomes as Mediators of the Systemic Adaptation to Endurance Exercise
  Mark A. Tarnopolsky, MD, PhD, FRCPC
Circulating MicroRNAs in Polycystic Ovary Syndrome
Louise T. Dalgaard, PhD, MSc

• Transformational Technologies in Islet Biology—From Omics to Imaging
The Visible Pancreas Project—Islets in Health and Diabetes
Martha L. Campbell-Thompson, DVM, PhD
Imaging Mass Spectrometry—Molecular Microscopy in the New Age of Discovery
Richard Caprioli, PhD
Single Cell Omics
Åsa Segerstolpe, PhD
In Situ and In Vivo Imaging of Human Islet Cell Physiology
Stephan Speier, PhD

4:15 p.m.-5:10 p.m.
Current Issues
• Cardiovascular Outcomes Trials (CVOTs) in Diabetes—Shall We Continue or Change Course?
  Continue—CVOTs Are Worth the Expense for the Knowledge Gained
  Steven P. Marso, MD
  Change Course—We Need to Refocus Our Approach and Questions
  Darren K. McGuire, MD, MHS

4:15 p.m.-6:15 p.m.
Symposia
• The Many Faces of Hypoglycemia—Impact on Patient Health and Well-Being
  Hypoglycemia and Cardiovascular Mortality
  Stephen N. Davis, MBBS
  The Link between Hypoglycemia and Arrhythmias
  Simon J. Fisher, MD, PhD
  Impact of Hypoglycemia on the Brain—Insights from Structural and Functional Neuroimaging
  Silvia Mangia, PhD
  Impact of Hypoglycemia on Patient-Reported Outcomes and Quality of Life
  Linda Gonder-Frederick, PhD

• Data, Data, Everywhere and Not a Pattern to Be Found
  Blood Glucose Meter—Interpreting Clinical Data
  Alison B. Evert, MS, RD, CDE
  Ambulatory Glucose Profile (AGP)—The Picture Says It All
  Mary L. Johnson, RN, BS, CDE
  Professional Continuous Glucose Monitoring—Avoiding Pitfalls and Optimizing Outcomes
  Patricia Knutsen, NP-C, RN, MSN, ACNS-BC, CDE
  Personal-Use Continuous Glucose Monitoring—Constructive Conversations with Your Patients
  Margaret Pellizzari, MS, MBA, RN, CDE, CDTC

5:20 p.m.-6:15 p.m.
Current Issues
• Should Metformin Remain the First-Line Therapy for Type 2 Diabetes?
  Yes—Metformin’s Efficacy, Safety, and Role as Initial Therapy Are Well Established
  Vanita R. Aroda, MD
  No—Change Is Overdue—Better Options Are Available
  Alice Y.Y. Cheng, MD, FRCPC

6:30 p.m.-8:30 p.m.
• ADA Education Recognition Program Symposium—Implementing Technology-Enabled Diabetes Care Management Processes for Population Health—Conception, Build, Implementation, Outcomes, and Sustainability
  Setting the Stage
  Michelle F. Magee, MD, MB, BCh, LRCPsI
  Implementation of the Diabetes Boot Camp in a Multipayer System
  Gretchen A. Youssef, MS, RD, CDE
  Learning from Outcomes, Sustainability, and Spread
  Carine M. Nassar, MS, RD, CDE

• Have You Seen Your Mother, Baby? Placenta-Derived Biomarkers of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus
  Circulating Exosomes in Gestational Diabetes Mellitus—Potential Role on Insulin Sensitivity during Gestation
  Carlos Salomon, PhD, DMedSc, MSc
  MicroRNAs in Maternal-Placenta-Fetal Communication and Pregnancy Health
  Yoel Sadovsky, MD
  Lipid Metabolism and How It Affects Fetal Growth
  Perrie F. O’Tierney-Ginn, PhD
  The Placenta Microbiome
  Samuel Parry, MD

• Genetics and Type 2 Diabetes in Youth
  Monogenic Diabetes—Results from SEARCH
  Catherine Pihoker, MD
  Prevalence of Monogenic Diabetes in Youth with Type 2 Diabetes—Results from the TODAY Study
  Rachelle Gandica, MD
  All Type 2 Diabetes Isn’t the Same, but When Is It Atypical?
  Siri Atma W. Greeley, MD, PhD
  Metformin Response among Youth with Type 2 Diabetes—Impact of Ethnicity/Genes
  Elvira Isganaitis, MD, MPH

Antibiotic Duration for the Treatment of Osteomyelitis—Who Said Six Weeks Was Enough?
Edgar J.G. Peters, MD, PhD
When In Vivo Stainless Steel Is the Best Antibiotic
F. Javier Aragón Sánchez, MD, PhD

• ADA Education Recognition Program Symposium—Implementing Technology-Enabled Diabetes Care Management Processes for Population Health—Conception, Build, Implementation, Outcomes, and Sustainability
  Setting the Stage
  Michelle F. Magee, MD, MB, BCh, LRCPsI
  Implementation of the Diabetes Boot Camp in a Multipayer System
  Gretchen A. Youssef, MS, RD, CDE
  Learning from Outcomes, Sustainability, and Spread
  Carine M. Nassar, MS, RD, CDE

• Have You Seen Your Mother, Baby? Placenta-Derived Biomarkers of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus
  Circulating Exosomes in Gestational Diabetes Mellitus—Potential Role on Insulin Sensitivity during Gestation
  Carlos Salomon, PhD, DMedSc, MSc
  MicroRNAs in Maternal-Placenta-Fetal Communication and Pregnancy Health
  Yoel Sadovsky, MD
  Lipid Metabolism and How It Affects Fetal Growth
  Perrie F. O’Tierney-Ginn, PhD
  The Placenta Microbiome
  Samuel Parry, MD

• Genetics and Type 2 Diabetes in Youth
  Monogenic Diabetes—Results from SEARCH
  Catherine Pihoker, MD
  Prevalence of Monogenic Diabetes in Youth with Type 2 Diabetes—Results from the TODAY Study
  Rachelle Gandica, MD
  All Type 2 Diabetes Isn’t the Same, but When Is It Atypical?
  Siri Atma W. Greeley, MD, PhD
  Metformin Response among Youth with Type 2 Diabetes—Impact of Ethnicity/Genes
  Elvira Isganaitis, MD, MPH

Antibiotic Duration for the Treatment of Osteomyelitis—Who Said Six Weeks Was Enough?
Edgar J.G. Peters, MD, PhD
When In Vivo Stainless Steel Is the Best Antibiotic
F. Javier Aragón Sánchez, MD, PhD

• ADA Education Recognition Program Symposium—Implementing Technology-Enabled Diabetes Care Management Processes for Population Health—Conception, Build, Implementation, Outcomes, and Sustainability
  Setting the Stage
  Michelle F. Magee, MD, MB, BCh, LRCPsI
  Implementation of the Diabetes Boot Camp in a Multipayer System
  Gretchen A. Youssef, MS, RD, CDE
  Learning from Outcomes, Sustainability, and Spread
  Carine M. Nassar, MS, RD, CDE

• Have You Seen Your Mother, Baby? Placenta-Derived Biomarkers of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus
  Circulating Exosomes in Gestational Diabetes Mellitus—Potential Role on Insulin Sensitivity during Gestation
  Carlos Salomon, PhD, DMedSc, MSc
  MicroRNAs in Maternal-Placenta-Fetal Communication and Pregnancy Health
  Yoel Sadovsky, MD
  Lipid Metabolism and How It Affects Fetal Growth
  Perrie F. O’Tierney-Ginn, PhD
  The Placenta Microbiome
  Samuel Parry, MD

• Genetics and Type 2 Diabetes in Youth
  Monogenic Diabetes—Results from SEARCH
  Catherine Pihoker, MD
  Prevalence of Monogenic Diabetes in Youth with Type 2 Diabetes—Results from the TODAY Study
  Rachelle Gandica, MD
  All Type 2 Diabetes Isn’t the Same, but When Is It Atypical?
  Siri Atma W. Greeley, MD, PhD
  Metformin Response among Youth with Type 2 Diabetes—Impact of Ethnicity/Genes
  Elvira Isganaitis, MD, MPH
• ADA Diabetes Care Symposium—Using Continuous Glucose Monitoring and Smart Devices to Control Glucose when It Matters Most
  Intensive Glycemic Treatment during Pregnancy
  Helen R. Murphy, MD, FRACP
  Continuous Glucose Monitoring and CSII in the Hospital
  Guillermo E. Umpierrez, MD, CDE, FACP, FACE
  Closed-Loop Systems for Type 1 Diabetes in Youth—Children Are Not Just Small Adults
  Jennifer Sherr, MD, PhD
  “Profiles in Progress” Plaque Presentations

• HIV and Diabetes—The Double Whammy
  Epidemiology of Diabetes Mellitus among People Living with HIV
  Phyllis Tien, MD
  HIV and the Heart
  Priscilla Hsue, MD
  Antiretroviral Therapy, Lipodystrophy, and Dyslipidemia
  Carl Grunfeld, MD, PhD
  Management of Diabetes in HIV
  Todd T. Brown, MD, PhD

• Overcoming Challenges in Islet Transplantation—Engineering and Protecting Beta Cells
  Engineering the Biohub—Clinical Use of Alternate Transplant Sites
  David Baidal, MD
  Physiologic Demands, A Challenge for Stem-Cell Generated Beta-Cell Implants
  Daniel Pipeleers, MD, PhD
  Overcoming the Immuno-suppression Barrier in Islet Transplant—Modulating the Local Environment to Protect Transplanted Cells
  Lonnie D. Shea, PhD
  Novel Encapsulation Approaches to Prevent Rejection and Recurrent Autoimmunity
  Tejal Desai, PhD

• Hepatokines and Metabolic Regulation—A Liver-Centric Point of View
  Fetuin B Links Hepatic Steatosis to Altered Glucose Homeostasis
  Matthew J. Watt, PhD
  New Insights into the Physiology and Pharmacology of FGF21
  Steven Kliewer, PhD
  ApoJ Is a Novel Hepatokine Regulating Muscle Glucose Metabolism and Insulin Sensitivity
  Young-Bum Kim, PhD
  Foxo-Regulated Hepatokines Regulate Hepatic Insulin Resistance
  Morris F. White, PhD

• Turning Up the Heat—New Regulators of Thermogenesis in Mice and Humans
  Blocking Follicle-Stimulating Hormone (FSH) Induces Thermogenic Adipose Tissue and Reduces Body Fat
  Mone Zaidi, MD, PhD
  Lipolysis in Brown Adipose Tissue Is Not Essential for Cold-Induced Thermogenesis in Mice
  Liqing Yu, MD, PhD
  Critical Review of the Energy Sources of Brown Adipose Tissue Thermogenesis in Humans
  André C. Carpenter, MD
  Cold-Induced Adipokines in Thermogenesis and Metabolism
  Yu-Hua Tseng, PhD

Oral Presentations
10:15 a.m.-11:15 a.m.
• President, Health Care & Education Address
  Felicia Hill-Briggs, PhD, ABPP
• Outstanding Educator in Diabetes Award Lecture
  Jackie Boucher, MS, RD

11:30 a.m.-12:30 p.m.
Professional Interest Group Sessions
• The Best and Worst Practices in Managing the Diabetic Foot
  Opening Remarks
  Barry Rosenblum, DPM
  Panel Discussion
  Neal R. Barshes, MD, MPH
  Lawrence A. Lavry, DPM
  Misaki Kiguchi, MD, MBA
  Edgar J.G. Peters, MD, PhD

• Update on Nonnutritive Sweeteners and Cardiometabolic Health
  Evidence for Effect of Nonnutritive Sweeteners on Cardiometabolic Health in Adults
  Judith Wylie-Rosett, EdD, RD
  Potential Effects of Early Life Exposure to Nonnutritive Sweeteners
  Dylan Mackay, MSc, PhD

• Reframing Exercise—The Surprising Science behind Motivating Patients to Be More Physically Active
  Concepts and Science
  Michelle Segar, PhD, MPH

Mini-Symposium
• Quantifying Diabetes—Genomics, Electronic Health Records, and Automated Control
  The Type 2 Diabetes Knowledge Portal
  Jason A. Flannick, PhD
  Diabetes Data Science—Linking Genotype, Electronic Health Records, and Real-Time Monitoring
  Philip E. Bourne, PhD, FACMI
  Adaptive Automated Control of Diabetes
  Francis J. Doyle III, PhD
  Question and Discussion Period

General Poster Session
11:30 a.m.-1:30 p.m.
Moderated Poster Discussions
1:45 p.m.-3:45 p.m.

Case Studies

- Monogenic Diabetes Testing
  Is Ready for Prime Time—
  Integrating Genetics into Your Practice

Recognizing and Diagnosing
Monogenic Diabetes
Louis H. Philipson, MD, PhD
Genetic Testing for Monogenic Diabetes—Whom to Test, What and How to Order?
Miriam Udler, MD, PhD
Genetic Testing for Monogenic Diabetes—What Do the Results Mean, What Do I Do Next?
Liana K. Billings, MD, MMS
Genetic Testing for Monogenic Diabetes—How Does It Impact the Patient?
Susi Perkowitz

Symposia

- The Resurgence of Triglyceride-Rich Lipoproteins as an important Target in the Treatment of Dyslipidemia
  New Insights into the Metabolism of Triglyceride-Rich Lipoproteins
  Ira J. Goldberg, MD
  Do Triglyceride-Rich Lipoproteins Cause Atherosclerosis?
  Anne Tybjærg-Hansen, MD, DMSc
  The Chylomicronemia Syndrome—A Potentially Fatal Complication of Elevations in Triglyceride-Rich Lipoproteins in Patients with Diabetes
  Alan Chait, MD
  New and Old Approaches to Lower Triglyceride-Rich Lipoproteins
  Sotirios Tsimikas, MD, FACC, FAHA, FSCAI

- Making a Difference in Five Minutes—Interventions in Diabetes for Anyone (With Richard R. Rubin Award Lecture)
  Richard R. Rubin Award Lecture
  Tim Wysocki, PhD, ABPP
  Five-Minute ABS (Adherence, Bite-Sized)
  Andrew Riley, PhD
  Intervening in Diabetes Distress
  Lawrence Fisher, PhD, ABPP
  Chasing and Talking about Numbers—It’s Not a Game
  Jill Weissberg-Benchell, PhD, CDE
  Working with Couples and Diabetes—I’m Not a Child and You’re Not My Parent
  Paula M. Trief, PhD

- Role of Exercise in Regulating Mitochondrial Dynamics
  Overview—Metabolic Regulation of Mitochondrial Dynamics
  David C. Chan, MD, PhD
  Exercise and Mitochondrial Turnover
  David A. Hood, PhD
  Mitofusin 2 as a Driver of Energy Metabolism and Insulin Signaling
  Antonio Zorzano, PhD
  Regulation of Skeletal Muscle Mitochondrial Remodeling in Type 2 Diabetes
  John P. Kirwan, PhD

- National Implementation and Dissemination of Research to Improve Patient Safety and Reduce Hypoglycemia
  Introduction—Federal Role in Patient Safety and Hypoglycemia
  Christine S. Lee, PharmD, PhD
  National Population Health Management of Hypoglycemia
  Damian Everhart, RN, PhD
  Implementing the Risk Prediction Algorithm for Hypoglycemia into Routine Clinical Practice
  Nilay D. Shah, PhD
  Development of an Outcome-Based Hypoglycemia Performance Measure to Optimize Patient Health
  Matthew Pickering, PharmD
  Implementing the National Action Plan in the Transforming Clinical Practice Initiative
  M. Carol Greenlee, MD, FACE, FACP

- The Diabetes Do-It-Yourself (DIY) Revolution
  The Diabetes DIY Technology Revolution—How Patients Are Changing the Innovation Pipeline and Care
  Jason B. Wittmer, MD, FCCP
  Supporting and Communicating with Patients about DIY Diabetes—The Clinician’s Role
  Lorenzo Sandini, MD
  The Data behind DIY Diabetes—Opportunities for Collaboration and Ongoing Research
  Dana M. Lewis, BA
  The Front Lines of DIY Diabetes—State of the State and Closing the Loop
  Joyce M. Lee, MD, MPH

- Exploring the Next Frontier in Diabetes Pharmacology
  Stretching It Out—Very-Long-Acting Agents and Implantable Technologies for Drug Delivery in Diabetes
  Carlos A. Alvarez, PharmD, MSc, MSCS, BCPS
  Peptides Gone “Oral” or Other Delivery Routes (Transnasal, Transdermal, Inhaled, etc.) for Glucose-Lowering Agents
  Hugh Smyth, PhD
  “Smart” (Gluco-Sensing) Insulins—Nanotechnology and Other Approaches
  Arturo J. Vegas, PhD
  The Dual/Triple Peptides—Premise, Technologies, and Clinical Promise
  Richard DiMarchi, PhD

- Lessons Learned from the Environmental Determinants of Diabetes in the Young (TEDDY) Study—Insights into Early Autoimmune Type 1 Diabetes
  The First-Appearing Islet Autoantibodies—Genetics and Prospects of Different Etiologies
  Jeffrey Krischer, PhD
  Maternal Dietary Supplement Use and the Development of Islet Autoimmunity in the Offspring
  Jill M. Norris, PhD
  Gestational Infections and the Trigger of Islet Autoimmunity
  Kristian F. Lynch, PhD
  Association between Gastrointestinal Infections and Onset of Islet Autoimmunity in the TEDDY Study
  Maria Lönnrot, MD, PhD
  Family History of Diabetes and Other Autoimmune Diseases—Effect on Development of Islet Autoimmunity and Type 1 Diabetes in TEDDY Children
  Riitta Veijola, MD, PhD
  My Child Is Islet Autoantibody Positive—Impact on Parent Understanding of Their Child’s Diabetes Risk
  Suzanne Bennett Johnson, PhD

Speakers and presentation titles are subject to change.
The Intestine in the Regulation of Metabolism, Immunity, and Insulin Sensitivity
Frank J. Gonzalez, PhD
The Role of the Gut in Regulating Whole-Body Metabolism—Insights from Bariatric Surgery
Darleen A. Sandoval, PhD
Enteroendocrine Functions of the Intestine
Daniel J. Drucker, MD
Fishing for Regulators—Live Imaging of Intestinal Lipid Flux through Lipoproteins and Lipid Droplets Using the Zebrafish
Steven A. Farber, PhD
Steering the Right Course for Diabetes Management—Clinical Perspectives
What’s Next after Metformin Is the Wrong Question—Type 2 Diabetes Remission as a New Treatment Paradigm
Hertzel C. Gerstein, MD, MSc, FRCPC
What Is the Best Diet? Building a Portfolio of Nutritional Recommendations Based on Current Evidence
Donald D. Hensrud, MD, MPH
What Is the Best Activity/Exercise? Recommendations for Healthy Living
Donald D. Hensrud, MD, MPH
Joint ADA/Chinese Diabetes Society Symposium—Glucose and Lipid Metabolism—Novel Mechanisms and Targets
cGAS Pathway Activation in Obesity-Induced Metabolic Dysfunction
Feng Liu, MD, PhD
Mitochondrial Dynamics and Hepatic Metabolism
Chih-Hao Lee, PhD
The Role of SGLT2 in Diabetes-Associated Hypertension
Xiaoying Li, MD, PhD
Ameliorating Diabetic Nephropathy by Transcriptional Suppression of TGFβ1
Junli Liu, PhD
Joint ADA/ISPAD Symposium—25 Years after the Announcement of the DCCT Results—What Is the Status of Type 1 Diabetes in Youth, and How Can We Do Better?
State of Pediatric Type 1 Diabetes Mellitus in the United States
Joseph Wolfsdorf, MB, BCH
State of Pediatric Type 1 Diabetes Mellitus in the World
Sabine E. Hofer, MD, PhD
What Can We Do Differently? The European Experience
Knut Dahl-Jørgensen, MD, PhD
Where Do We Go from Here? Lessons Learned after 25 Years of the DCCT
Rose Gubitosi-Klug, MD, PhD
Neurotransmitters in the Islet
GABA Signaling in the Context of Beta-Cell Neogenesis
Patrick Collombat, PhD
Glutamate Action (Serotonin, Dopamine)
Siegfried Ussar, PhD
GABA Synthesis in the Islet
Edward Phelps, PhD
Glutamate in the Beta Cell, from Metabolism to Signaling
Pierre Maechler, PhD
Beta-Cell Dedifferentiation—True or False?
Why Do Beta Cells in Type 2 Diabetes Survive So Long?
Peter C. Butler, MD
Beta-Cell Dedifferentiation—One-Way or Round Trip?
Piero Marchetti, MD, PhD
Fragile Beta-Cell Identity—From Metabolic Stress to Loss of Beta-Cell Transcription Factors
Avital Swisa, PhD
Beta-Cell Stress and Dedifferentiation—Moving Beyond Semantics
Mark A. Magnuson, MD
Online and Mobile Support—Wading through the Noise
Can Diabetes Apps Make Our Lives Easier?
Adam Brown, BS
Evaluating Mobile Apps for Disease Self-Management
David Fedele, PhD
Building Cybersecurity into Connected Diabetes Devices
David C. Klonoff, MD
Mitochondrial Dynamics, Metabolism, and Insulin Action
Transcriptional Control of Mitochondrial Biogenesis and Function
Anastasia Krali, PhD
Role of Mitochondrial Dynamics in Neuronal Energy Sensing
Sabrina Diano, PhD
Fanning the Flames—Mitochondrial Flux in Diabetes and Fatty Liver Disease
Shawn C. Burgess, PhD
Phospholipid Turnover and Mitochondrial Metabolism in Skeletal Muscle
Katsu Funai, PhD
Neurotransmitters in the Islet
GABA Signaling in the Context of Beta-Cell Neogenesis
Patrick Collombat, PhD
Glutamate Action (Serotonin, Dopamine)
Siegfried Ussar, PhD
GABA Synthesis in the Islet
Edward Phelps, PhD
Glutamate in the Beta Cell, from Metabolism to Signaling
Pierre Maechler, PhD
Oral Presentations
4:00 p.m.-6:00 p.m.
Symposia
Nutrition and the Gut Microbiome
State-of-the-Art Lecture—Nutrition and the Gut Microbiome
Joseph Petrosino, PhD
Gut Microbiome in Relation to Autoimmunity and Type 1 Diabetes
Tommi Vatanen, PhD
Impact of the Gut Microbiome on Energy Regulation, Weight Management, and Eating Disorders
Ian Carroll, PhD
Online and Mobile Support—Wading through the Noise
Can Diabetes Apps Make Our Lives Easier?
Adam Brown, BS
Evaluating Mobile Apps for Disease Self-Management
David Fedele, PhD
Building Cybersecurity into Connected Diabetes Devices
David C. Klonoff, MD
Joint ADA/ISPAD Symposium—25 Years after the Announcement of the DCCT Results—What Is the Status of Type 1 Diabetes in Youth, and How Can We Do Better?
State of Pediatric Type 1 Diabetes Mellitus in the United States
Joseph Wolfsdorf, MB, BCH
State of Pediatric Type 1 Diabetes Mellitus in the World
Sabine E. Hofer, MD, PhD
What Can We Do Differently? The European Experience
Knut Dahl-Jørgensen, MD, PhD
Where Do We Go from Here? Lessons Learned after 25 Years of the DCCT
Rose Gubitosi-Klug, MD, PhD
Joint ADA/Chinese Diabetes Society Symposium—Glucose and Lipid Metabolism—Novel Mechanisms and Targets
cGAS Pathway Activation in Obesity-Induced Metabolic Dysfunction
Feng Liu, MD, PhD
Mitochondrial Dynamics and Hepatic Metabolism
Chih-Hao Lee, PhD
The Role of SGLT2 in Diabetes-Associated Hypertension
Xiaoying Li, MD, PhD
Ameliorating Diabetic Nephropathy by Transcriptional Suppression of TGFβ1
Junli Liu, PhD
Mitochondrial Dynamics, Metabolism, and Insulin Action
Transcriptional Control of Mitochondrial Biogenesis and Function
Anastasia Krali, PhD
Role of Mitochondrial Dynamics in Neuronal Energy Sensing
Sabrina Diano, PhD
Fanning the Flames—Mitochondrial Flux in Diabetes and Fatty Liver Disease
Shawn C. Burgess, PhD
Phospholipid Turnover and Mitochondrial Metabolism in Skeletal Muscle
Katsu Funai, PhD
Neurotransmitters in the Islet
GABA Signaling in the Context of Beta-Cell Neogenesis
Patrick Collombat, PhD
Glutamate Action (Serotonin, Dopamine)
Siegfried Ussar, PhD
GABA Synthesis in the Islet
Edward Phelps, PhD
Glutamate in the Beta Cell, from Metabolism to Signaling
Pierre Maechler, PhD
SUNDAY, JUNE 24, 2018

8:00 a.m.-10:00 a.m.

Symposia

• The Where and Why of Diabetic Neuropathy
  Insight into the Why—The Importance of Sphingolipids
  Vera Fridman, MD
  Insight into the Why—The Importance of Bioenergetic Deficits
  Lucy M. Hinder, PhD
  Seeing What They Are Feeling—Central Nervous System Neuroimaging
  Dinesh Selvarajah, MB, ChB, MRCP, PhD
  Seeing What They Are Feeling—Peripheral Nervous System Neuroimaging
  Niels Ejskjaer, MD, PhD

• Blood Flow to the Toe
  Diabetes Mellitus and Peripheral Arterial Disease
  Michael H. Criqui, MD, MPH
  Role of Cardiology and the Diabetic Foot—Addressing the Heart of the Problem
  Carlos Mena, MD, FACC, FSCAI
  Endovascular Revascularization—How Low Do You Need to Go?
  Neal R. Barshes, MD, MPH
  Vascular Bypass Is Not a Thing of the Past—The Limitations of Endovascular Revascularization
  Misaki Kiguchi, MD, MBA

• Building a Case for Getting Reimbursement or Payment for Behavioral Health in Diabetes
  Using Economic Data to Build the Case for Behavioral Health Care
  David Janicke, PhD, ABPP
  Implementing a System for Reimbursement of Psychosocial Screening in Diabetes Care
  Danny C. Duke, PhD
  Cost-Effectiveness Evaluations—How to Evaluate the Financial Impact of Care
  Dmitry Dukhovny, MD, MPH

Building a Reimbursement Model to Support Behavioral Health in a Pediatric Obesity Clinic
Marilyn Sampilo, PhD, MPH

• NDEP Symposium—Diabetes Prevention, Care, and Education in the Digital Age
  Welcome/Introductions
  M. Sue Kirkman, MD
  Preventing Type 2 Diabetes in the Digital Age—The National Diabetes Prevention Program
  Ann L. Albright, PhD, RD
  Telemedicine for Improvements in Diabetes Care and Education Outcomes
  Linda Siminerio, RN, PhD
  Improving Diabetes Treatment Access and Outcomes Using Mobile Health Tools—Examples of Evidence-Based Solutions
  John D. Piette, PhD
  Digital Tools and Technology for Optimizing Diabetes Care among Latinos
  Athena Philis-Tsimikas, MD
  Future Research/Concluding Remarks
  Judith E. Fradkin, MD

• Unrecognized (Occult) Metabolic Conditions in Women with Gestational Diabetes Mellitus that Predict Metabolic Complications Later in Life
  Metabolic Disorders in Relation to Fatty Liver and Visceral Adiposity in Pregnancy
  Joel G. Ray, MD, MSc, FRCPC
  Sleep and Glucose Metabolism in Pregnancy
  Sirimon Reutrakul, MD
  Adverse Childhood Experiences, Adverse Family Environment, and Gestational Diabetes
  Susan Marshall Mason, PhD, MPH
  Gestational Diabetes and Depression—Co-occurrence, Prediction, Later Complications, and Intervention
  Beth Bailey, PhD

• Prioritizing Injectable Therapies in Type 2 Diabetes
  Basal Insulin or GLP-1 Agonist—Which Agent First, When?
  Juan P. Frias, MD
  Therapy Progression after Basal Insulin—GLP-1 Agonist vs. Prandial Insulin vs. Premixed Insulins
  Helena W. Rodbard, MD
  How Differences in GLP-1 Agonists Impact Treatment, With or Without Basal Insulin
  Juris Meier, MD
  When Should Premixed Basal Insulin/GLP-1 Agonists Be Considered?
  Vivian Fonseca, MD

• Challenges and Hope in Finding a Cure for Type 1 Diabetes
  The Challenge of Dose Selection
  Marc A. Gavin, PhD
  The Challenge of Heterogeneity in Disease Progression
  Todd M. Brusko, PhD
  Harnessing Heterogeneity in Response to Therapy
  Matthew DuFort, PhD
  Applying Mechanistic Insights from Natural History to Therapy
  Martin J. Hessner, PhD

• Precision Medicine in Diabetes
  Emerging Imaging Modalities (Muscle, Brain, Liver, Pancreas) in Diabetes
  Michael Roden, MD
  Measure What Is Measurable and Make Measurable What Is Not
  Claudio Cobelli, PhD
  Genetics and Precision Medicine for Diabetes
  Stephen S. Rich, PhD
  VIP Therapeutics—Individualized Treatment Based on a Virtual Image of the Patient-Researcher Perspective
  Boris P. Kovatchev, PhD
  Bench to Bedside—Precision Individualized Medicine for Diabetes—A Clinician’s Perspective
  Ananda Basu, MBBS, MD
ADVANCE PROGRAM

• ADA Diabetes Symposium—Emerging Areas of Islet Biology
  LncRNA Regulation of Islet Biology
  Lori Sussel, PhD
  Checkpoint Inhibitor-Induced Diabetes
  Kevan C. Herold, MD
  Beta-Cell Failure in Type 1 Diabetes
  Clayton E. Mathews, PhD

Oral Presentations
10:15 a.m.-11:45 a.m.
• President, Medicine & Science Address
  Jane E.B. Reusch, MD
• Banting Medal for Scientific Achievement
  Gerald I. Shulman, MD, PhD

12:00 p.m.-1:00 p.m.
Mini-Symposia
• The Importance of the Functional Characteristics of HDL
  Importance of the Antioxidant/Anti-inflammatory Effects of HDL
  in Preventing Atherosclerosis
  Mohamad Navab, PhD
  Importance of Reverse Cholesterol Transport in Preventing Atherosclerosis
  Alan T. Remaley, MD
  Question and Discussion Period

• Update on Diabetic Retinopathy Clinical Trials
  DRCR.net Update on Anti-VEGF and Steroids
  Jennifer K. Sun, MD, MPH
  Update on Retinopathy Outcomes in GLP-IRA Trials
  Wiley A. Chambers II, MD
  Question and Discussion Period

• Update on the Genetics of Type 1 and Type 2 Diabetes
  Update on the Genetics of Type 1 Diabetes
  Grant Morahan, BSc (Hons), PhD
  Update on the Genetics of Type 2 Diabetes
  Mark McCarthy, MD
  Question and Discussion Period

Professional Interest Group Sessions
• Moving Past the Randomized Controlled Trial—Understanding the Need for Implementation Science in Diabetes Care
  The Uptake of Behavioral Diabetes Research into Routine Health Care
  Gretchen A. Piatt, PhD, MPH
  Use of Pragmatic Trials in Diabetes Prevention and Control
  Laura A. Young, MD, PhD
  Scale Up, Spread, and Sustainability of Diabetes Prevention Programs
  Rachel G.A. Tabak, PhD, RD

The Future of Diabetes Education—“Live” Educator and “Virtual” Coach Partners in Care
A Voice-Enabled Diabetes Self-Management Program That Addresses Mood—The DiaBetty Experience
Olusika Ajilore, MD, PhD
Your Virtual Diabetes GluCoach—Always Ready
Holger Semsch
The Marriage of a Live Educator and Virtual Coach
Joe Solowiejczyk, RN, MSW, CDE

Beyond HbA1c in Pediatric Diabetes—Is It Time to Look at Other Outcomes?
It Is Time to Incorporate Other Glycemic Outcomes
Roy W. Beck, MD, PhD
HbA1c Is Still a Key Measure
William V. Tamborlane, MD
It Is Time to Stress Nonglycemic Outcomes
Lori Laffel, MD, MPH

Clinical Centers and Programs Session I
Diabetes Management in Hospitalized Patients with End-Stage Renal Disease/Dialysis
Jennifer Wyckoff, MD
A Multidisciplinary Team’s Approach to Reduce Inpatient Insulin-Related Hypoglycemia
Celeste C. Thomas, MD, MS

Improving Glycemic Control and Decreasing the Risk of Hypoglycemia in Diabetic Patients in a Long-Term Care Facility
Janice L. Gilden, MD, MS, FCP, FACE, FAAS
Piloting a Quality Improvement Project in an Advanced Practice Provider-Led Hospitalist Team to Standardize Perioperative Insulin Management in Patients with Acute Diabetic Foot Ulcers and/or Infections
Luigi F. Meneghini, MD, MBA

General Poster Session/Moderated Poster Discussions
1:00 p.m.-2:00 p.m.
Session Break (Take this opportunity to visit the Exhibit and Poster Halls)

2:15 p.m.-3:00 p.m.
• Kelly West Award for Outstanding Achievement in Epidemiology Lecture
  Catherine C. Cowie, PhD

2:15 p.m.-4:15 p.m.
Symposia
• Joint ADA/ASN Symposium—Management of Patients with Progressing Diabetic Kidney Disease (DKD)
  Pathophysiology of DKD and Glycemic Goals in Patients with Low Glomerular Filtration Rate
  Bernard Zinman, MD
  How and When to Modify Diabetes Medications as Glomerular Filtration Rate Declines
  Mark E. Molitch, MD
  Specific Considerations for Lipid Lowering in DKD
  Christoph Wanner, MD
  Specific Considerations for Blood Pressure Control in DKD
  George Bakris, MD
• Innovative Strategies to Improve the Inpatient Experience
  Patients’ Own Diabetes Devices—To Wear or Not to Wear?
  Donna Jornsay, MS, BSN, CPNP, CNS, CDE, CDTC, BC-ADM
  Diabetes Care Coordination—When the Hospital and Home Regimen Are at Odds
  Laura B. Hieronymus, DNP, MSEd, RN, MLDE, BC-ADM, CDE, FAADE
  Implementing a Patient-Centered Interdisciplinary Diabetes Care Model
  Sandra Hardee, PharmD, CDE
  Building an Inpatient Glycemic Management Team
  Stacey A. Seggelke, DNP, ACNS-BC, BC-ADM, CDE

• Aerobic Exercise in the Prevention of Cognitive Decline in Diabetes
  Genetic and Metabolic Factors in Progression of Alzheimer’s Disease
  Jill Morris, PhD
  Exercise-Mediated Improvements in Memory and Cognition
  Henriette van Praag, PhD
  The Effects of Aerobic Exercise on the Brain in Older Adults with Prediabetes
  Christina E. Hugenschmidt, PhD
  Impaired Cerebral Blood Flow during Exercise in Type 2 Diabetes Mellitus
  Johannes van Lieshout, MD

• The National Diabetes Prevention Program—From Research to Practice to National Policy
  Status of the National Diabetes Prevention Program—From Access to Uptake
  Ann L. Albright, PhD, RD
  Implementing the New Medicare Diabetes Prevention Program Service
  Elizabeth Matthews, MPA
  CDC Recognition—What You Need to Know
  Elizabeth K. Ely, MS
  Where Are We with Medicaid Coverage?
  Patricia Shea, MPH, MA

• Joint ADA/JDRF Symposium—Current Management of Type 1 Diabetes in Youth—What Are the Options?
  Insulin Therapy in Youth with Type 1 Diabetes Mellitus—Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion?
  Hood Thabit, MD, PhD
  Monitoring Glycemia in Youth with Type 1 Diabetes Mellitus—Meter Blood Glucose, Continuous Glucose Monitoring, or Both?
  Gregory P. Forlenza, MD
  Psycho/Social Support—The Sometimes Forgotten Part of the Management
  Maureen Monaghan, PhD
  Nutrition and Exercise—More Relevant than Ever in the Era of Obesity?
  Peter Adolfsson, MD, PhD
  Beyond HbA1c—How Are We Managing Type 1 Diabetes Mellitus Comorbidities?
  Petter Bjornstad, MD

• Addressing Unique Challenges in Diabetes Management
  An Update on Cystic Fibrosis-Related Diabetes and Its Treatment
  Antoinette Moran, MD
  Glycemic Issues and Therapeutic Approaches in Patients Receiving Cancer Therapy
  Tahseen A. Chowdhury, MD, FRCP
  Managing the Stroke Patient with Diabetes
  Walter Kernan, MD
  Heart Failure Outcomes in Diabetes Cardiovascular Outcomes Trials—An Evolving Landscape
  Javed Butler, MD, MPH, MBA

• Joint ADA/Diabetes UK Symposium—Cell Therapy for Diabetes—International Progress
  The UK Islet Transplant Consortium—Utilizing Centralized Islet Isolation and Expanded Donor Criteria
  Shareen Forbes, MB, ChB, PhD, FRCP
  Progress towards Islets as a Clinically Approved Therapy in the U.S.
  Jose Oberholzer, MD
  Utilizing Diabetes Technology in Transplantation—Is There a Role for Continuous Glucose Monitors?
  Marie-Christine Vantyghem, MD, PhD

Islet Transplant to Reduce Progression of Microvascular Complications
David M. Thompson, MD

• Fuel Driving Function—Lipidic Roles in Different Tissues
  Lipid Metabolism and Angiogenesis in the Retina
  Lois E.H. Smith, MD, PhD
  Muscle Lipid Uptake during Exercise
  Peter Plomgaard, MD, PhD
  Regulation of Lipid Metabolism by ANGPTL4
  Carlos Fernández-Hernando, PhD
  Molecular Mechanisms Underlying Intravascular Lipolysis
  Anne Beigneux, PhD

• Ordering from the Weight-Loss Menu in the Era of Precision Medicine for Obesity
  Predicting Obesity Using Genetic Information
  Ruth Loos, PhD
  Precision Nutrition—Using Gene-Diet Interaction Data to Guide Nutrition Therapy
  Lu Qi, MD, PhD
  Lifestyle Precision Medicine—Using Genetic and Behavioral Data to Guide Lifestyle Interventions
  Jeanne M. McCaffery, PhD
  Toward More Precise Surgical Approaches
  Anita P. Courcoulas, MD, MPH

• More to Mitochondria in the Beta Cell
  The Bioenergetics of the Beta Cell—Should Coupling Factors Be Reevaluated?
  David G. Nicholls, PhD
  Intrinsic and Extrinsic Signals Governing Beta-Cell Mitochondrial Quality Control
  Scott A. Soleimanpour, MD
  Drp1 Is Required for the Metabolic Amplifying Pathway of Insulin Secretion
  Gregory Ku, MD, PhD
  Effects of Genetic Variations on Mitochondrial Function and Morphology
  Simone E. Baltrusch, PhD
Oral Presentations

4:30 p.m.-6:30 p.m.

Symposia

- Neuro- and Glial-Vascular Effects in the Pathogenesis of Diabetic Retinopathy
  Proteomic Analysis of Neuro-degenerative Changes in Preclinical Diabetic Retinopathy
  Jeffrey M. Sundstrom, MD, PhD
  Vascular Effects on Glia and Neurons using OCTA
  Amani Fawzi, MD
  Müller Cells and Their Effect on Vasculature and Neuronal Cells
  Susanne Mohr, PhD
  The Role of Photoreceptors and Photoreceptor Metabolic Modulation with Light Therapy in Diabetic Retinopathy
  Timothy S. Kern, PhD

- The Veterans Affairs Diabetes Trial (VADT) at 15 Years
  Design of the VADT and VADT Follow-Up Study
  Wyndy L. Wiitala, PhD
  Macrovascular Events in the VADT-F Study
  Peter D. Reaven, MD
  Renal and Other Microvascular Outcomes in the VADT-F Study
  Nicholas V. Emanuele, MD
  Clinical Perspective
  Rodney Hayward, MD

- Low-Carbohydrate Diets—Potential Benefits, Risks, and Costs
  Low-Carbohydrate Diets for the Metabolic Management of Adults with Type 2 Diabetes
  Jeannie Tay, PhD
  Low-Carbohydrate Diets for Children—Impacts and Potential Risks of Dietary Restriction
  Martin I. de Bock, FRACP
  Environmental Sustainability and Impact of Low-Carbohydrate Diets
  Timothy Griffin, PhD

- Diabetes Prevention—What Are We Preventing?
  Preventing Diabetes vs. Treating Prediabetes
  Leigh Perreault, MD
  Preventing Microvascular Disease
  Lena Carlsson Ekander, MD, PhD
  Preventing Macrovascular Disease
  Jean-Louis Chiasson, MD
  Preventing Cancer, Cognitive Decline, and Physical Impairment
  Jill P. Crandall, MD

- Joint ADA/AACC Symposium—Refining Measurement of A1C—Do We Know What It Means?
  What A1C Results Don’t Tell You (about Risk for Complications)
  Richard M. Bergenstal, MD
  Correcting A1C Results for Erythrocyte Lifespan—Problem Solved?
  John M. Higgins, MD
  Assessment of A1C in Patients with Hemoglobin Disorders
  David B. Sacks, MB, ChB
  Should A1C Targets Differ among Ethnic Groups?
  Robert M. Cohen, MD

- Academia-Industry Collaborations—Key Considerations
  Clinical Research Outcomes
  Joel Lexchin, MD
  Challenges and Opportunities in Nutrition Research
  W. Timothy Garvey, MD
  Academia-Industry Collaborations in Diabetes Trials
  John B. Buse, MD, PhD
  Addressing Potential Bias and Conflicts of Interest
  Ameet Sarpatwari, JD, PhD

- Beyond Single Nucleotide Polymorphisms—Building on Knowledge of the Genetic Architecture of Diabetes
  Type 2 Diabetes in the Trans-Omics for Precision Medicine (TOPMed) Program
  James B. Meigs, MD, MPH
  Do Epigenetic Mechanisms Affect the Pathogenesis of Type 2 Diabetes?
  Charlotte Ling, PhD

Pharmacogenetics
Amber L. Beitelshes, PharmD, MPH, FAHA, FCCP
Applications of the Type 1 Diabetes Risk Score
Richard A. Oram, MD, PhD

- Novel Pathogenetic Pathways in Type 1 Diabetes—What Can We Learn from Cancer Immunotherapy?
  Immune Checkpoints in Cardiovascular Disease
  Andrew H. Lichtman, MD, PhD
  Cancer Immunotherapy-Induced Autoimmune Diabetes and Endocrinopathies—The Memorial Sloan-Kettering Cancer Center Experience
  Monica Girotra, MD
  Checkpoint Inhibitor-Induced Type 1 Diabetes—The University of Texas MD Anderson Case Studies
  Conor J. Best, MD

- New Angles in Adipose Biology
  Adipocyte Turnover, Aging, and Insulin Resistance
  Matthew Steinhauser, MD
  Phosphoproteomic Analysis of Insulin Resistant Adipocytes
  David E. James, PhD
  Adipose Tissue Lipolysis in Humans
  Michael D. Jensen, MD
  CEACAM1 along the Adipocyte-Hepatocyte Axis and Systemic Metabolism
  Sonia M. Najjar, PhD

- Joint ADA/EASD Symposium—Central Control of Glucose Homeostasis
  Central Nervous System Neurons That Control Glucose Production
  Martin G. Myers, Jr., MD, PhD
  Central Nervous System that Control Glucose Production TBD
  Central Glucose Sensing in the Defense against Hypoglycemia
  Bernard Thorens, PhD
  Leptin Action on POMC Neurons Regulates the Coordinated Metabolic Responses to Fasting
  Joel K. Elmquist, DVM, PhD
• Alpha Cells—New Sources of Beta Cells?  
  A Hepatic–Islet–Alpha-Cell Axis Integrates Amino Acid Availability with Alpha-Cell Mass  
  Danielle Dean, PhD  
  Alpha-Cell Transdifferentiation  
  Kenichiro Furuyama, MD, PhD  
  Regulation of Alpha-Cell Mass and Function by Nutrient Signaling  
  Ernesto Bernal-Mizrachi, MD  
  Transcriptional Control of Alpha-Cell Fate  
  Takaaki Matsuoka, MD, PhD

Oral Presentations

MONDAY, JUNE 25, 2018

8:00 a.m.-10:00 a.m.

Symposia

• Role of the Kidney in Heart Health  
  Natural History of Nephropathy and Associated Cardiovascular Risk  
  Julia Scialla, MD  
  Sodium-Hydrogen Exchange and the Cardiorenal Axis  
  Julie A. Lovshin, MD, PhD  
  Impact of Tubuloglomerular Feedback  
  Christopher T. Chan, MD, FRCP  
  Cardiovascular Risk Reduction in the Patient with Nephropathy  
  Janani Rangaswami, MD, FACP

• Intervening in the Lived Experiences and Social Context of Those with Diabetes  
  Understanding the Social Context of Managing Diabetes—What’s Life Really Like?  
  Evan A. Los, MD  
  Intervention Targeting the Social Determinants of Health in Youth with Repeat Diabetic Ketoacidosis—Novel Interventions in Children’s Healthcare (NICH) Works  
  Lena Teplitsky, MPH  
  Integrating Social and Behavioral Interventions for Diabetes in Primary Care  
  Danielle M. Hessler, PhD  
  Using the Electronic Medical Record with Patient-Reported Outcomes for Social Determinants of Health Screening and Resource Linkage in Diabetes Care  
  Erika Cottrell, PhD, MPP

• Who Do You Think You Are? Heterogeneity of Obesity and Gestational Diabetes Mellitus  
  Heterogeneity of Gestational Diabetes—Physiologic and Genetic Characterization  
  Marie-France Hivert, MD  
  Heterogeneity in Gestational Diabetes Mellitus—A View from the Beta Cell  
  Thomas A. Buchanan, MD  
  Metabolic Heterogeneity in Obese Pregnancies—Looks Can Be Deceiving  
  Linda A. Barbour, MD, MSPH, FACP  
  Treatment of Gestational Diabetes Mellitus Based on Underlying Pathophysiology  
  Maia N. Feghali, MD

• Type 2 Diabetes in Youth—Update on the Current State of Knowledge on Complications  
  Natural History of Type 2 Diabetes Mellitus in Youth—Different than in Adults?  
  Fida Bacha, MD  
  Cardiovascular Disease Risk Factors in Youth with Type 2 Diabetes Mellitus—Time to Be More Aggressive in the Management?  
  Amy S. Shah, MD  
  Microvascular Complications in Youth with Type 2 Diabetes Mellitus—How Common Are They and When Do We Treat?  
  Amy K. Motti, MD  
  Psychosocial and Behavioral Self-Care Challenges in Youth with Type 2 Diabetes Mellitus—The Not So Hidden Iceberg  
  Elizabeth M. Venditti, PhD

• Effectiveness of Telemedicine in Underserved Communities  
  Project Extension for Community Healthcare Outcomes (ECHO)—Diabetes Education and Training  
  Evan Klass, MD  
  Success of Telehealth Eye Care in Indian Health Service  
  Mark B. Horton, OD, MD  
  Telemedicine Care in Rural Communities  
  Michele Heisler, MD, MPA  
  eHealth for Diabetes Care in Latino Communities  
  A. Enrique Caballero, MD

• Clinical Trials for Type 1 Diabetes—Current, Emerging, and Novel  
  What We Have Learned and Plan to Learn from TrialNet Studies  
  Manuela Battaglia, PhD  
  Increasing the Pace of Research—Novel Clinical Trial Designs  
  Jeffrey Krischer, PhD  
  Combination Immunotherapy for Type 1 Diabetes—The TrialNet ATG/GCSF Study  
  Michael Haller, MD  
  From Mechanism to Clinical Trial—Methyldopa for Type 1 Diabetes Prevention  
  Aaron Michels, MD

• Recognition of Depression, Diabetes, and Dementia—Resetting Clinical Priorities  
  Neuroimaging and Neuro-modulation in Obesity and Type 2 Diabetes  
  Maria A. Guzzardi, PhD  
  Insulin Resistance and Cognition  
  Sophia Frangou, MD, MSc, PhD, FRCPsych  
  Research Perspective of Diabetes and Depression—The Neuroendocrine Link  
  Sherita Golden, MD, MHS  
  What Is the Role of Diabetes Treatments in the Treatment of Psychiatric Disorders?  
  Roger S. McIntyre, MD, FRCP

• Metabolism and the Beta Cell  
  Disallowed Genes  
  Timothy Pullen, PhD  
  Glucose Metabolism  
  Richard G. Kibbey, MD, PhD  
  Regulation of Islet Beta-Cell Glucose Cycling by IGRP/G6PC2  
  Richard M. O’Brien, PhD  
  Functional and Metabolomic Consequences of KATP Channel Inactivation in Human Islets  
  Diva D. De León-Crutchlow, MD, MSCE
10:15 a.m.-11:45 a.m.

- National Scientific & Health Care Achievement Awards Presentation
- Outgoing Scientific Achievement Award Lecture
  Lora K. Heisler, PhD

12:00 p.m.-1:00 p.m.

Mini-Symposia

- Special Topics in Hypoglycemia
  New Definition of Hypoglycemia—Why Does It Matter?
  Simon R. Heller, MD, FRCP
  Economic Impact of Severe Hypoglycemia
  Philip C. McEwan, PhD
  Question and Discussion Period

- Overcoming Gender Gaps in Science
  Gender Gaps in Science—The Clinician Scientist Perspective
  Elizabeth R. Seaquist, MD
  Overcoming Gender Gaps in Science—A Health Education and Behavioral Discipline Perspective
  Felicia Hill-Briggs, PhD, ABPP
  Gender Gaps in Science—Panel Discussion
  Jane E.B. Reusch, MD

Professional Interest Group Sessions

- The Lancet Commission on Diabetes—Societal Solutions to Combat Diabetes
  Diabetes—A Global Epidemic Requiring Societal Solutions
  Edward W. Gregg, PhD
  Act Now to Change Environments for Preventing Diabetes and Evaluate Impacts
  Nicholas Wareham, PhD
  Strengthening the System to Improve Diabetes Care and Access to Cost-Effective Drugs
  Juliana C.N. Chan, MD
  Population and Health System Surveillance
  Jonathan E. Shaw, MD, FRACP, FRCP (UK), FAAHMS

- Should All Pregnant Women with Type 1 Diabetes Use Continuous Glucose Monitoring from Planning Pregnancy until after Breastfeeding?
  Pro
  Denice S. Feig, MD, MSc, FRCP
don
  Elisabeth R. Mathiesen, MD, DMSc

- Clinical Centers and Programs Session II
  Endocrinology Telehealth Consultation Improved Glycemic Control Similar to Face-to-Face Visits in Veterans
  Neda Rasouli, MD
  Diabetes Telemedicine Development in the Great Plains
  Leslie Eiland, MD
  A Feasibility Study using Polaris, an Automated Lifestyle Health Navigator Mobile App, to Optimize Metabolic Index
  Ping H. Wang, MD
  Integrating Technology with Remote Diabetes Management
  Joseph A. Aloj, MD

- Defining a Healthy Diet—Do Fats or Carbohydrates Matter More?
  It's All about the Fats!
  Allison Sylvetsky, PhD
  It's All about the Carbs!
  Viswanathan Mohan, MD, PhD, DSc

2:15 p.m.-4:15 p.m.

Symposia

- Easing Disease Management Burden for Older Adults
  Assessing Functional Decline in Older Adults—Influences in Decision Making
  Barbara Resnick, PhD, RN, CRNP
  Polypharmacy and the Older Adult—Easing the Medication Burden
  Leigh Ann Mike, PharmD, BCPS, BCGP
  Tailoring the Diabetes Regimen—One Size Does Not Fit All
  Mary C. Ballin, GNP-BC, CDE
  Creating Educational Interventions for Older Adults
  Elizabeth A. Beverly, PhD

- Cost-Related Nonadherence to Diabetes Care
  Introduction—Financial Incentives in Health Insurance—What Is Their Role?
  A. Mark Fendrick, MD
  Cost-Related Nonadherence in Medicare Beneficiaries
  Carol M. Mangione, MD, MSPH
  Social Determinants of Cost-Related Nonadherence with Diabetes Care
  Minal R. Patel, PhD, MPH
  Effect of High-Deductible Health Insurance on Diabetes Care and Outcomes
  J. Frank Wharam, MB, BCh, BAO, MPH
  Level of Deductible in an Insurance Plan Affects Medical Care Use in Individuals with Diabetes
  Anuradha Jetty, MPH

- The Restoring Insulin Secretion (RISE) Study in Youth and Adults—Baseline Data and Results of the Pediatric Medication Study
  General Introduction
  Griffin P. Rodgers, MD
  Background
  Rationale for Intervention Studies
  Addressing the Pathophysiology of Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes in Youth and Adults
  David A. Ehrmann, MD
Study Designs—Pediatric Medication, Adult Medication, and Adult Surgery Protocols
Sharon L. Edelstein, ScM

Baseline Data Comparing Youth and Adults
Demographics, Insulin Sensitivity, and Cardiovascular Disease Risk Factors
Kieren J. Mather, MD
Contrasts in Beta-Cell Function Based on the Hyperglycemic Clamp and OGTT
Silva A. Arslanian, MD

RISE Pediatric Medication Study Results
Comparisons of Baseline Data by Intervention Arms
Tamara S. Hannon, MD, MS
Primary Outcome
Kristen J. Nadeau, MD, MS
Secondary Outcomes and Adverse Events
Philip S. Zeitler, MD, PhD

- Adipose Signaling and the Central Nervous System in the Control of Obesity
  Astrocyes and the Regulation of Energy Homeostasis
  Kate Ellacott, PhD
  New Cell Types Involved in Hypothalamic Obesity
  Linus T.-Y. Tsai, MD, PhD
  IKKβ, from Atherogenesis to Adipogenesis and Beyond
  Changcheng Zhou, PhD
  Adipose Inflammation
  Ajay Chawla, MD, PhD

- Diversity Affairs—Impact of Genetic Variability and Sex on Integrative Metabolism and Disease Risk
  Genetic Heterogeneity in Murine Responses to High-Fat Diet
  Brian Parks, PhD
  Genetic Diversity of Lifespan Modulation in Mice
  Colin Selman, PhD
  Systems Network Modeling of Genetic Risks of Metabolic Diseases
  Xia Yang, PhD

Dissecting the Role of Estrogen Receptors in the Regulation of Metabolic Homeostasis in Muscle
Espen E. Spangenburg, PhD

Oral Presentations
- Edwin Bierman Award Lecture
  Alessandro Doria, MD, PhD, MPH
- Vivian Fonseca-Nagendran Award Presentation
  Rita Rastogi Kalyani, MD, MHS

4:30 p.m.-6:30 p.m.

Current Issues
- Albuminuria—Two Debates
  Should Patients with Microalbuminuria and Normal Blood Pressure be Treated with Renin Angiotensin Aldosterone System Blockade?
  Yes, All Patients Should Be Treated
  Peter Rossing, MD
  No, Not All Patients Should Be Treated
  Robert Nelson, MD, PhD
  Should the Level of Albuminuria be a Treatment Target?
  Yes, Albuminuria Should Be a Therapeutic Target
  Dick de Zeeuw, MD, PhD
  No, Albuminuria Should Not Be a Therapeutic Target
  Merlin Thomas, MB, ChB, PhD, FRACP

Symposia
- Clinical Strategies for Prevention and Management of Hypoglycemia
  Hypoglycemia—Who Is at Risk and Who Is Most Likely to Be Harmed?
  Emily B. Schroeder, MD, PhD
  Preventing Hypoglycemia in Type 1 Diabetes through Patient Education
  Stephanie A. Amiel, MD, FRCP
  Preventing Hypoglycemia in Type 2 Diabetes through More Appropriate Treatments
  Geremia B. Bolli, MD
  Leveraging Technology to Detect, Prevent, and Treat Hypoglycemia
  Bruce A. Buckingham, MD

- Diabetes and Psychosocial Risk Factors in the Hispanic Community Health Study/Study of Latinos
  Diabetes Awareness, Treatment, Glycemic Control, and Access to Health Insurance—Longitudinal Relationships from the Hispanic Community Health Study/Study of Latinos
  Neil Schneiderman, PhD
  Health Behaviors, Psychosocial Factors, Obesity, and Risk for Type 2 Diabetes—Findings from the Hispanic Community Health Study/Study of Latino Youth
  Alan M. Delamater, PhD
  Cultural and Psychosocial Risk Factors for Type 2 Diabetes and Metabolic Syndrome in the Hispanic Community Health Study/Sociocultural Ancillary Study
  Carmen R. Isasi, MD, PhD

- Using mHealth for Obesity Treatment and Weight Management
  State-of-the-Art—Perspectives towards Sustained Behavior Change
  Deborah Tate, PhD
  Digital DPP—Evaluation of mHealth for Outcomes and Cost of Diabetes Prevention
  Rick Chapman, PhD, MS
  Utilization and Perception—Behavioral Components of the Practice-Based Opportunities for Weight Reduction Hopkins Trial
  Janelle Coughlin, PhD

- Insulin Therapy—To the Future and Back
  Fast and Furious or just Marketing Fiction? Expectations from New and Developing Rapid Acting Insulins
  Tim Heise, MD
  Which Patients Should Receive New Ultra-Long-Acting Basal Insulin Products?
  Carol H. Wysham, MD
  When and How to Use Neutral Protamine Hagedorn and Regular in Patients with Type 2 or Type 1 Diabetes
  Dace Trence, MD
  Concentrated Insulin Products
  Wendy S. Lane, MD
ADVANCE PROGRAM

• Mechanistic Insights from Rare Conditions and Opportunities for Novel Therapeutics
  Modeling Insulin Variants
  Fabrizio Barbetti, MD, PhD
  Wolfram Syndrome and Wolfram Spectrum Disorder
  Fumihiko Urano, MD, PhD
  Lipodystrophies
  Atul Chopra, MD, PhD
  Severe Obesity
  Sadaf Farooqi, PhD, FRCP, FMedSci

• Clinical Updates in Beta-Cell Replacement Therapy
  Defining Outcomes for Beta-Cell Replacement Therapy—A Summary from the 2017 IPITA/EPITA Igls Consensus Workshop
  Michael R. Rickels, MD, MS
  An Update from the CIT-07 Trials—Quality of Life and Metabolic Outcomes of Islet Allotransplant
  Camillo Ricordi, MD
  Who Is the Ideal Patient for Alloislet Transplant? Predictive Models for Successful Transplant Outcomes from the CITR
  Franca B. Barton, MS
  Challenges in Islet Transplantation—Risks and Barriers to Islet Transplant for Type 1 Diabetes
  Peter A. Senior, MBBS, PhD

• The Islet in Type 1 Diabetes—What’s New?
  tRNA Hypomethylation—A Novel Mechanism of Beta-Cell Demise in Diabetes
  Miriam Cnop, MD, PhD
  Islet Resident Macrophages/T Cells
  David M. Harlan, MD
  KIRA8, Shift Back to Adaptive UPR in Type 1 Diabetes
  Feroz R. Papa, MD, PhD
  Islet Endoplasmic Reticulum Stress
  Anath Shalev, MD

Oral Presentations

TUESDAY, JUNE 26, 2018
8:00 a.m.-10:00 a.m.

Symposia

• Cardiorenal Effects of Glucose-Lowering Therapies
  SGLT2i, GLP-1RA, and DPP-4i and Effects on Proteinuria—From Physiology to Clinical Practice
  Hiddo Lambers Heerspink, PhD
  Other Renal Protective Agents—Endothelin Antagonists, Mineralocorticoid Antagonists, and Novel Potassium Binders
  Daniël H. van Raalte, MD, PhD
  Heart Failure Management in the Era of EMPA-REG Outcome and CANVAS Program
  Mikhail N. Kosiborod, MD
  How to Put the Pieces Together—How Will SGLT2i and GLP-1RA/DPP-4i Agents Work Together, and with Other Newer Agents?
  David Cherney, MD, PhD

• Multigenerational Effects of Exercise
  Epigenetic Effects of Exercise on Metabolism
  Romain Barrés, PhD
  Early-Life and Multigenerational Programming of Physical Activity
  Theodore Garland, Jr., PhD
  Maternal Exercise and Diabetes Risk in Future Generations
  Laurie J. Goodyear, PhD
  Fit Fathers—Epigenetic Reprogramming of Sperm by Exercise
  Michelle Lane, PhD

• Management of Diabetes in a Surgical Patient
  Preparation for Elective Surgery
  Rajesh Garg, MD
  Glucose Management in the Operating Room
  Jesse Ehrenfeld, MD, MPH
  Postoperative Hyperglycemia
  Francisco J. Pasquel, MD
  Reducing Readmissions after Surgery
  Kathleen M. Dungan, MD, MPH

Obesity in Type 1 Diabetes—An Evolving Challenge
  Epidemiology and Physiology
  Cynthia L. Ogden, PhD
  Nutrition and Exercise Recommendations
  Jackie Boucher, MS, RD
  Challenges of Insulin Use in the Obese Patient with Type 1 Diabetes
  David Russell-Jones, MD
  Pharmacotherapy for Obesity in Type 1 Diabetes
  Jennifer N. Clements, PharmD, FCCP, BCPS, CDE, BCACP
  Bariatric Surgery in Patients with Type 1 Diabetes—What Do We Know?
  Ali Aminian, MD, FACS

• Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018
  Introduction and Methods
  Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP
  The Rationale and Importance of Antihyperglycemic Treatment
  Judith E. Fradkin, MD
  Apostolos Tsapas, MD, PhD, MSc
  Personalized Approach Based on Patient Characteristics and Comorbidities
  Peter Rossing, MD
  Deborah J. Wexler, MD
  Therapeutic Options—Lifestyle Management and Pharmacologic Treatment
  Walter Korman, MD
  Geltrude Mingrone, MD, PhD
  Strategies for Implementing Antihyperglycemic Treatment Plan
  David D’Alessio, MD
  Chantal Mathieu, MD, PhD
  Key Knowledge Gaps, Question and Discussion Period
  John B. Buse, MD, PhD
• **Diabetes in Rural America**
  Disparities in the Prevention and Management of Diabetes in Rural America
  Shivani A. Patel, PhD
  Burden of Diabetes and Its Complications among American Indians and Alaska Natives
  Spero M. Manson, PhD
  How to Improve Access in Rural America?
  Matthew F. Bouchonville, MD
  Policy Solutions to Improve Diabetes Care in Rural America
  Janice C. Probst, PhD

• **Aging and Insulin Sensitivity**
  Metformin Action in Aging and Cancer
  Alexander Soukas, MD, PhD
  Caloric Restriction and Aging—A Focus on Metabolism
  Rozalyn M. Anderson, PhD
  Metabolic Defects Induced by the Lifespan-Extending Drug Rapamycin
  Joseph A. Baur, PhD
  Mitochondria and Aging
  Jennifer Estall, PhD

• **Nutrient Sensing and Signaling in the Regulation of Metabolic Homeostasis**
  Amino Acids and Metabolic Health
  Mark A. Herman, MD
  Mechanisms of High-Fructose Diet-Induced Pathology in the Liver
  Dean R. Tolan, PhD
  The Influence of Diet on Maternal-Fetal Metabolic Programming
  Carrie McCurdy, PhD
  Nicotinamide Adenine Dinucleotide Metabolism and Energy Homeostasis
  Charles Brenner, PhD
  Nutrient Sensing and Oxidative Stress
  Danica Chen, PhD

• **G-Protein-Coupled Receptors—Structural Insights to Therapeutic Options**
  Leveraging G-Protein-Coupled Receptors and Structural Insights
  Roger K. Sunahara, PhD
  Designer G-Protein-Coupled Receptors to Dissect Metabolic Pathways
  Jürgen Wess, PhD
  Inhibition of Secretion by GPCR Regulation of the Exocytotic Fusion Machinery
  Heidi E. Hamm, PhD
  Targeting GLP-1 Receptor Trafficking to Improve Agonist Efficacy
  Alejandra Tomas, PhD

**10:15 a.m.-12:15 p.m.**

**Symposium**

• **SGLT Inhibition for Type 1 Diabetes Mellitus Management—How Far Have We Gone?**
  Understanding Metabolic Effects of SGLT Inhibition in Type 1 Diabetes to Explain and Avoid Increased Risk of Diabetic Ketoacidosis
  Ele Ferrannini, MD
  Clinical Efficacy and Safety of Dapagliflozin in Type 1 Diabetes—Evidence to Date!
  Paresh Dandona, MD
  Empagliflozin “Ease” Development Program to Support Regulatory Approval
  Julio Rosenstock, MD
  Sotagliflozin “In Tandem” Development Program to Support Regulatory Approval
  John B. Buse, MD, PhD
  Should a Cardiovascular-Renal Prevention Outcome Trial with an SGLT Inhibitor Be Warranted in Type 1 Diabetes Mellitus?
  David Cherney, MD, PhD
For more information please contact:

Phone:
1-800-DIABETES

E-mail:
conventionoperations@diabetes.org

Website:
scientificsessions.diabetes.org